

(86) Date de dépôt PCT/PCT Filing Date: 1997/12/02
(87) Date publication PCT/PCT Publication Date: 1998/06/11
(45) Date de délivrance/Issue Date: 2010/04/06
(85) Entrée phase nationale/National Entry: 1999/05/12
(86) N° demande PCT/PCT Application No.: US 1997/021992
(87) N° publication PCT/PCT Publication No.: 1998/024904
(30) Priorités/Priorities: 1996/12/02 (US60/032,224);
1997/12/01 (US08/980,872)

(51) Cl.Int./Int.Cl. *C12N 15/12* (2006.01),
A61K 38/17 (2006.01), *C07K 14/715* (2006.01),
C12N 15/11 (2006.01), *C12N 5/10* (2006.01),
C12Q 1/68 (2006.01), *G01N 33/566* (2006.01),
G01N 33/68 (2006.01)

(72) Inventeurs/Inventors:
LEVITT, ROY CLIFFORD, US;
GRASSO, LUIGI, US;
NICOLAIDES, NICHOLAS C., US;
HOLROYD, KENNETH J., US

(73) Propriétaire/Owner:
GENAERA CORPORATION, US

(74) **Agent:** DEETH WILLIAMS WALL LLP

(54) Titre : VARIANTS DE RECEPTEUR IL-9, UTILISES POUR LE TRAITEMENT ET LE DIAGNOSTIC DES ALLERGIES ATOPIQUE, Y COMPRIS L'ASTHME ET LES TROUBLES APPARENTES

(54) Title: IL-9 RECEPTOR VARIANTS, USEFUL IN TREATING AND DIAGNOSING ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS

[illegible]

(57) Abrégé/Abstract:

This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor (2). One embodiment of the invention is a variant of AAF2, wherein

(57) Abrégé(suite)/Abstract(continued):

codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

C12N 15/12, C07K 14/715, C12Q 1/68,
G01N 33/566, 33/68, A61K 38/17, C12N
5/10, 15/11

A3

(11) International Publication Number:

WO 98/24904

(43) International Publication Date:

11 June 1998 (11.06.98)

(21) International Application Number: PCT/US97/21992

(22) International Filing Date: 2 December 1997 (02.12.97)

(30) Priority Data:

60/032,224

2 December 1996 (02.12.96)

US

Not furnished

1 December 1997 (01.12.97)

US

(71) Applicant: MAGAININ PHARMACEUTICALS INC.
[US/US]; 5110 Campus Drive, Plymouth Meeting, PA
19462 (US).(72) Inventors: LEVITT, Roy, Clifford; 660 Marsten Green Court,
Ambler, PA 19002 (US). GRASSO, Luigi; 136 North
Bread Street, Philadelphia, PA 19106 (US). NICOLAIDES,
Nicholas, C.; 4 Cider Mill Court, Boothwyn, PA 19061
(US). HOLROYD, Kenneth, J.; 112 Mennonite Road,
Collegeville, PA 19426 (US).(74) Agents: GARRETT, Arthur, S. et al.; Finnegan, Henderson,
Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W.,
Washington, DC 20005-3315 (US).(81) Designated States: AU, CA, JP, European patent (AT, BE,
CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE).

Published

With international search report.

(88) Date of publication of the international search report:

5 November 1998 (05.11.98)

(54) Title: IL-9 RECEPTOR VARIANTS, USEFUL IN TREATING AND DIAGNOSING ATOPIC ALLERGIES INCLUDING
ASTHMA AND RELATED DISORDERS

Sequence Range: 215 to 1044

215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10100 10105 10110 10115 10120 10125 10130 10135 10140 10145 10150 10155 10160 10165 10170 10175 10180 10185 10190 10195 10200 10205 10210 10215 10220 10225 10230 10235 10240 10245 10250 10255 10260 10265 10270 10275 10280 10285 10290 10295 10300 10305 10310 10315 10320 10325 10330 10335 10340 10345 10350 10355 10360 10365 10370 10375 10380 10385 10390 10395 10400 10405 10410 10415 10420 10425 10430 10435 10440 10445 10450 10455 10460 10465 10470 10475 10480 10485 10490 10495 10500 10505 10510 10515 10520 10525 10530 10535 10540 10545 10550 10555 10560 10565 10570 10575 10580 10585 10590 10595 10600 10605 10610 10615 10620 10625 10630 10635 10640 10645 10650 10655 10660 10665 10670 10675 10680 10685 10690 10695 10700 10705 10710 10715 10720 10725 10730 10735 10740 10745 10750 10755 10760 10765 10770 10775 10780 10785 10790 10795 10800 10805 10810 10815 10820 10825 10830 10835 10840 10845 10850 10855 10860 10865 10870 10875 10880 10885 10890 10895 10900 10905 10910 10915 10920 10925 10930 10935 10940 10945 10950 10955 1096

**IL-9 RECEPTOR VARIANTS, USEFUL IN TREATING AND DIAGNOSING
ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS**

5

FIELD OF THE INVENTION

10 This invention describes biologic variability in the IL-9 receptor (Asthma
Associated Factor 2) (SEQ ID NO1) and relates these sequence variants to
susceptibility to asthma, atopic allergy, and related disorders. This invention
also teaches methods that utilize these IL-9 receptor sequence variants for the
diagnosis of susceptibility or resistance to asthma and atopic allergy. In
15 addition, methods are described that use variant IL-9 receptors in the
development of pharmaceuticals for asthma which depend on the regulation of
IL-9 activity.

BACKGROUND OF THE INVENTION

20 Inflammation is a complex process in which the body's defense system
combats foreign entities. While the battle against foreign entities may be
necessary for the body's survival, some defense systems improperly respond
to foreign entities, even innocuous ones, as dangerous and thereby damage
surrounding tissue in the ensuing battle.

25 Atopic allergy is a disorder where genetic background dictates the response
to environmental stimuli. The disorder is generally characterized by an

increased ability of lymphocytes to produce IgE antibodies in response to ubiquitous antigens. Activation of the immune system by these antigens also leads to allergic inflammation which may occur after their ingestion, penetration through the skin, or after inhalation. When this immune activation occurs and pulmonary inflammation ensues, this disorder is broadly characterized as asthma. Certain cells are important in this inflammatory reaction in the airways and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells/basophils that store inflammatory mediators and bind IgE, and eosinophils that release additional mediators. These inflammatory cells accumulate at the site of allergic inflammation, and the toxic products they release contribute to the tissue destruction related to the disorder.

While asthma is generally defined as an inflammatory disorder of the airways, clinical symptoms arise from intermittent airflow obstruction. It is a chronic, disabling disorder that appears to be increasing in prevalence and severity.¹ It is estimated that 30-40% of the population suffer with atopic allergy, and 15% of children and 5% of adults in the population suffer from asthma.¹ Thus, an enormous burden is placed on our health-care resources in the treatment of these disorders.

Both the diagnosis and treatment of asthma and related disorders are problematic.¹ In particular, the assessment of inflamed lung tissue is often difficult, and frequently the cause of the inflammation cannot be determined. Although atopic asthma is an ecogenetic disorder, knowledge about the particular variant genes has only recently been discovered. Methods to detect these genetic variations and their role in inflammation, diagnosis and prognosis remain to be determined. What is needed in the art is the development of technology to expedite the diagnosis of atopic asthma that specifically relates to variation in genes responsible for susceptibility/resistance to this atopic disease.

Current treatments suffer their own set of disadvantages. The main therapeutic agents, β -agonists, reduce the symptoms, i.e., transiently improve pulmonary functions, but do not affect the underlying inflammation so that lung tissue remains in jeopardy. In addition, constant use of β -agonists results in desensitization which reduces their efficacy and safety.² The agents that can diminish the underlying inflammation, the anti-inflammatory steroids, have their own known list of side effects that range from immunosuppression to bone loss.²

Because of the problems associated with conventional therapies, alternative treatment strategies have been evaluated.³⁸⁻³⁹ Glycophorin A,³⁷ cyclosporin,³⁸ and a nona peptide fragment of IL-2,³⁶ all inhibit interleukin-2 dependent T lymphocyte proliferation.²⁸ They are, however, known to have many other effects.² For example, cyclosporin is used as an immunosuppressant after organ transplantation. While these agents may represent alternatives to steroids in the treatment of asthmatics,³⁶⁻³⁹ they inhibit interleukin-2 dependent T lymphocyte proliferation and potentially critical immune functions associated with homeostasis. What is needed in the art is technology to expedite the development of therapeutics that are specifically designed to treat the cause, and not the symptoms, of atopic asthma. These therapies represent the most likely way to avoid toxicity associated with nonspecific treatment. The therapies would selectively target a pathway, which is downstream from immune functions, such as IL-2 mediated T lymphocyte activation, that is necessary for the development of asthma and which would explain the episodic nature of the disorder and its close association with allergy. Nature demonstrates that a pathway is the appropriate target for asthma therapy when biologic variability normally exists in the pathway and individuals demonstrating the variability are not immunocompromised or ill except for their symptoms of atopic asthma.

Because of the difficulties related to the diagnosis and treatment of atopic allergies including asthma, the complex pathophysiology of these disorders is

under intensive study. While these disorders are heterogeneous and may be difficult to define because they can take many forms, certain features are found in common among asthmatics. Examples of such features include abnormal skin test response to allergen challenge, eosinophilia in the lung, bronchial hyperresponsiveness (BHR), bronchodilator reversibility, and airflow obstruction.³⁻¹⁰ These expressions of asthma related traits may be studied by quantitative or qualitative measures.

In many cases, elevated IgE levels are correlated with BHR, a heightened bronchoconstrictor response to a variety of stimuli.^{4,6,8,9} BHR is believed to reflect the presence of airway inflammation,^{6,8} and is considered a risk factor for asthma.¹¹⁻¹² BHR is accompanied by bronchial inflammation, including eosinophil infiltration into the lung and an allergic diathesis in asthmatic individuals.^{6,8,13-18}

A number of studies document a heritable component to atopic asthma.^{4,10} Family studies, however, have been difficult to interpret since these disorders are significantly influenced by age and gender, as well as many environmental factors such as allergens, viral infections, and pollutants.¹⁹⁻²¹ Moreover, because there is no known biochemical defect associated with susceptibility to these disorders, the mutant genes and their abnormal gene products can only be recognized by the anomalous phenotypes they produce.

The functions of IL-9 and the IL-9 receptor (the IL-9 pathway) now extend well beyond those originally recognized. While the IL-9 pathway serves as a stimulator of T cell growth, this cytokine is also known to mediate the growth of erythroid progenitors, B cells, mast cells, and fetal thymocytes.^{22,23} The IL-9 pathway acts synergistically with IL-3 in causing mast cell activation and proliferation.²⁴ The IL-9 pathway also potentiates the IL-4 induced production of IgE, IgG, and IgM by normal human B lymphocytes,²⁵ and the IL-4 induced release of IgE and IgG by murine B lymphocytes.²⁶ A role for the IL-9 pathway in the mucosal inflammatory response to parasitic infection has also been demonstrated.^{27,28}

Nevertheless, it is not known how the sequence of the IL-9 receptor specifically correlates with atopic asthma and bronchial hyperresponsiveness. It is known that IL-9 binds to a specific receptor expressed on the surface of target cells.^{23,29,30} The receptor actually consists of two protein chains: one protein chain, known as the IL-9 receptor, binds specifically with IL-9; the other protein chain is shared in common with the IL-2 receptor.²³ In addition, a cDNA encoding the human IL-9 receptor has been cloned and sequenced^{23,29,30} This cDNA codes for a 522 amino acid protein which exhibits significant homology to the murine IL-9 receptor. The extracellular region of the receptor is highly conserved, with 67% homology existing between the murine and human proteins. The cytoplasmic region of the receptor is less highly conserved. The human cytoplasmic domain is much larger than the corresponding region of the murine receptor.²³

The IL-9 receptor gene has also been characterized.³⁰ It is thought to exist as a single copy in the mouse genome and is composed of nine exons and eight introns.³⁰ The human genome contains at least four IL-9 receptor pseudogenes. The human IL-9 receptor gene has been mapped to the 320 kb subtelomeric region of the sex chromosomes X and Y.²³

In spite of these studies, no variants of the IL-9 receptor gene have been discovered. There is, therefore, a specific need for genetic information on atopic allergy, asthma, bronchial hyperresponsiveness, and for elucidation of the role of IL-9 receptor in the etiology of these disorders. This information can be used to diagnose atopic allergy and related disorders using methods that identify genetic variants of this gene that are associated with these disorders. Furthermore, there is a need for methods utilizing the IL-9 receptor variants to develop therapeutics to treat these disorders.

SUMMARY OF THE INVENTION

Applicants have discovered natural variants of the human IL-9 receptor (also known as Asthma Associated Factor 2 or AAF2) and have linked these

variants to the pathogenesis of asthma and related disorders. These discoveries have led to the development of diagnostic methods, and methods to discover pharmaceuticals for the treatment of therapeutics for atopic asthma. In addition, applicants have determined that the IL-9 receptor is critical to a number of antigen-induced responses in mice, including bronchial hyperresponsiveness, eosinophilia and elevated cell counts in bronchial lavage, and elevated serum total IgE. These findings typify atopic asthma and the associated allergic inflammation.

Furthermore, applicants have determined that a G to A nucleic acid variant occurs at position 1273 of the cDNA (SEQ ID NO 2) which produces the predicted amino acid substitution of a histidine for an arginine at codon 344 of the human IL-9 receptor precursor protein. When the arginine residue occurs in both alleles in one individual, it is associated with less evidence of atopic asthma. Thus, applicants have identified the existence of a non-asthmatic phenotype characterized by arginine at codon 344 when it occurs in both IL-9 receptor gene products in one individual. As an additional significant corollary, applicants have identified the existence of susceptibility to an asthmatic, atopic phenotype characterized by a histidine at codon 344. Thus, the invention includes purified and isolated DNA molecules having such a sequence as well as the proteins encoded by such DNA.

Applicants have also determined that a splice variant of the IL-9R exists wherein the glutamine residue at position 173 of the IL-9R precursor protein has been deleted (SEQ ID NO 3) (Figure 5). Applicants have further shown that this variant is not able to transcribe a signal through the Jak-Stat pathway (Figure 15) and is unable to induce cellular proliferation upon stimulation with IL-9 (Figure 16); therefore, individuals with this allele would be less susceptible to atopic asthma and related disorders.

Applicants have further determined that a variant of the IL-9R genomic DNA exists wherein nt-213, a thymine residue in intron 5 (213 nt upstream from exon 6), has been converted to a cytosine nucleotide. It is likely that such a

variation can cause an increase in the frequency of the splice variant which removes the glutamine residue at the start of exon 6.

In addition, applicants have discovered a variant of IL-9R wherein exon 8 has been deleted (SEQ ID NO 4) which results in a change in reading frame and a premature stop codon in exon 9. Such a variant would most likely be prevented from transmitting a signal through the Jak-Stat pathway and, therefore, individuals with this allele would also be less susceptible to atopic asthma and related disorders.

The biological activity of IL-9 results from its binding to the IL-9 receptor and the consequent propagation of a regulatory signal in specific cells; therefore, IL-9 functions can be interrupted by the interaction of IL-9 antagonists with IL-9 or its receptor. Down regulation, i.e., reduction of the functions controlled by IL-9, is achieved in a number of ways. Administering antagonists that can interrupt the binding of IL-9 to its receptor is one key mechanism, and such antagonists are within the claimed invention. Examples include administration of polypeptide products encoded by the DNA sequences of a naturally occurring soluble form of the IL-9 receptor, wherein the DNA sequences code for a polypeptide comprising exons 2 and 3 (SEQ ID NO 5). Two other variations can produce soluble forms of the IL-9R receptor which comprise exons 2, 3 and 4 and in one case four amino acids from a different reading frame in exon 5 (SEQ ID NO 7) (Figure 7) and in the other case there are 27 amino acids from a different reading frame in exon 5 (SEQ ID NO 6) (Figure 6).

Methods to identify agonists and antagonists of the IL-9 receptor pathway can be identified by assessing receptor-ligand interactions which are well described in the literature. These methods can be adapted to high throughput automated assays that facilitate chemical screenings and potential therapeutic identification. Agonists are recognized by identifying a specific interaction with the IL-9 receptor. Loss of binding for a putative ligand which is labeled when a 100- to 1000-fold excess of unlabeled ligand is used is generally accepted as

evidence of specific receptor binding. Many labels and detection schemes can be used during these experiments. A similar loss of binding when increasing concentrations of test compound are added to a known ligand and receptor is also evidence for an antagonist.

5 Knowledge of the variant receptors provides the means to construct expression vectors that can be used to make soluble receptor for receptor binding assays. Mutagenesis of these soluble receptors can be used to determine which amino acid residues are critical to bind ligand and aid in the structure-based design of antagonists.

10 Cells lacking human IL-9 receptor can be transiently or stably transfected with expression vectors containing a variant receptor and used to assay for IL-9 pathway activity. These activities may be cellular proliferation, or prevention of apoptosis which have both been ascribed to the IL-9 pathway. These cells can be used to identify receptor agonists and antagonists as described above.

15 The methods discussed above represent various effective methods utilizing the variant forms of IL-9 receptor to develop therapeutics for atopic asthma and other related disorders.

A number of techniques have been described that may be used to diagnose atopic asthma that recognize single nucleotide variants in the IL-9 receptor
20 including DNA sequencing, restriction fragment length polymorphisms (RFLPs), allele specific oligonucleotide analyses (ASO), ligation chain reaction (LCR), chemical cleavage, and single stranded conformational polymorphism analyses (SSCP). A skilled artisan will recognize that the use of one or more of these techniques, as well as others in the literature, may be used to detect
25 one or more variations in the IL-9 receptor gene or mRNA transcript and are within the scope of the present invention.

Still other techniques may be used to detect amino acid variants in the IL-9 receptor including ELISAs, immunoprecipitations, Westerns, and immunoblotting. Thus, polyclonal and monoclonal antibodies which recognize
30 specifically the structure of the various forms of the IL-9 receptor are also

within the scope of this invention and are useful diagnostic methods for describing susceptibility or resistance to atopic asthma and related disorders.

The methods discussed above represent various effective methods for diagnosing atopic asthma and other related disorders.

5 Thus, applicants have provided methods that use the IL-9 receptor to identify antagonists that are capable of regulating the interaction between IL-9 and its receptor. More specifically, applicants provide a method for assaying the functions of the IL-9 receptor to identify compounds or agents that may be administered in an amount sufficient to down-regulate either the expression or
10 functions of the IL-9 pathway.

Having identified the role of the IL-9 pathway in atopic allergy, bronchial hyperresponsiveness and asthma, applicants also provide a method for the diagnosis of susceptibility and resistance to atopic allergy, asthma, and related disorders.

15 The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and, together with the description, serve to explain the principle of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

20 **Figure 1:** Schematic representation of the human IL receptor cDNA. Boxes depict exon 2 to 9 encompassing the coding region (relative size in scale, except the 3' untranslated part of exon 9, outlined by dashed line). Transmembrane region is encoded by exon 7, intracellular domain by exon 8 and 9, and the extracellular by exon 2 to 6. Arrows indicate polymorphisms or
25 aberrant splices affecting partial sequence of the exon; a) deletion of the first 5 or 29 nucleotides in exon 5; b) deletion of the first 3 nucleotides in exon 6 (codon 173); c) arg/gly polymorphism at codon 310; d) arg/his polymorphism at codon 344; e) polymorphism at codon 410+n consisting of either 8 or 9 serines; *) complete deletion of exon 3, 4 or 8.

Figure 2: Translated cDNA sequence of the wild type IL-9R precursor protein with Arg allele at codon 344 (nucleotides 1272-1274) and the 8 Ser/4 Asn repeats starting at codon 410 (nucleotides 1470-1472).

Figure 3: Translated cDNA sequence of the IL-9R precursor protein with the His allele at codon 344 (nucleotides 1272-1274) and the 9 Ser/4 Asn repeats starting at codon 410 (nucleotides 1470-1472).

Figure 4: Translated cDNA sequence of IL-9R precursor protein with the deletion of exon 8 causing a frame shift in exon 9, the production of 11 non-wild type amino acids and a premature stop codon.

Figure 5: Translated cDNA sequence of IL-9R precursor protein with the deletion of Glutamine at codon 173.

Figure 6: Translated cDNA sequence of IL-9R precursor protein with an alternate splice in exon 5 resulting in a premature stop codon and the production of 27 non-wild type amino acids.

Figure 7: Translated cDNA sequence of IL-9R precursor protein with an alternate splice in exon 5 resulting in a premature stop codon and the production of 4 non-wild type amino acids.

Figure 8: Translated cDNA sequence of IL-9R precursor protein with the deletion of exon 4 producing a stop codon as the first codon of exon 5.

Figure 9: Table showing the association between the IL-9 receptor genotype and atopic allergy. The Arg/Arg individuals are homozygous for the Arg allele with the 8 Ser/4 Asn repeats. The Arg/His individuals are heterozygous for the Arg allele with the 8 Ser/4 Asn repeats and the His allele with the 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn repeats in exon 9. The His/His individuals are homozygous for the His allele with the 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn repeats in exon 9. The Arg/Arg individuals are protected from atopic allergy. The Arg/His and His/His individuals are susceptible to atopic allergy ($P = 0.002$).

Figure 10: Map of the expression construct of the IL-9 receptor.

Figure 11: Western blot of recombinant IL-9 receptor proteins (left: Arg allele with the 8 Ser/4 Asn repeats; right: His allele with the 9 Ser/4 Asn repeats) using C terminal antibody probe in TK⁻ transfected cell line.

Figure 12: Expression of human IL-9 receptor variants in TS1 cells showing differential mobility between the Arg 344 variant with 8 Ser/4 Asn repeats (GR8) and His 344 variant with 9 ser/4 Asn repeats (GH9). A mobility shift is seen demonstrating differential post-translational modification of these two variant form of the IL-9 receptor.

Figure 13: XY specific amplimers for specific amplification of the IL-9 receptor gene. Pseudogenes on chromosomes 9, 10, 16, or 18 are not amplified by PCR. (M is mouse DNA, H is human DNA, and C is hamster DNA.)

Figure 14: Immunoreactivity of an anti-human IL-9 receptor neutralizing antibody with wild type and Delta-Q receptors. Panel A): COS7 cells were transiently transfected with the LXS_N vector alone (A and B), wild type IL-9R (C and D), Wild type IL-9R with 9 Ser residues starting with codon 410 (E and F), Δ-Q 173 variant (G and H) and Δ-Q 173 with 9 Ser residues starting at codon 410 (I and J) and sequentially incubated with MAB290 and anti-mouse IgG Texas Red-conjugated antibody (B,D,F,H and J) as described (Example 8). DAPI staining (A,C,E,G and I) was included to visualize every cell in the photographed field. Panel B): as in A) except that cells were first fixed/permabilized and then incubated with a C-terminal specific antibody (sc698) followed by incubation with anti-rabbit IgG Texas Red-conjugated antibody. Bar = 10 microns.

Figure 15: Activation of members of Jak, Stat, and Irs families via different variants of the human IL-9 receptor. TS1 cells expressing either GH9, ΔQGR8, or ΔQGH9 were starved for 6 hours and then treated for 5 minutes without cytokine (-), with murine IL-9 (m), or with human IL-9 (h). Cell extracts were immunoprecipitated with various antibodies specific for different members of Jak, Stat and Irs families. Immunoblots were first reacted with an

anti-phosphotyrosine antibody to detect only tyrosine-phosphorylated proteins and then stripped and reprobed with the same antibody used to immunoprecipitate each protein. GH9, Δ QGR8, Δ QGH9 are as indicated in Figure 16.

5 **Figure 16:** Proliferation of TS1 cells expressing different forms of human IL-9 receptor. Cells were seeded in quadruplicate in 96-well plates (1000/well) and treated without cytokine or with murine or human IL-9 (5 ng/ml). A colorimetric assay was performed 7 days later to determine cell number, and the ratio between treated/untreated cells (% control) was calculated to assess growth rate. LxSN = cells transfected with the empty vector; GR8 is wild type IL-9R; GH9 is the His 344 variant with 9 Ser residues starting at codon 410; Δ QGR8 and Δ QGH9 are the Δ Q173 variants on the wild type and the His 344 + 9 - Ser background, respectively.

10 **Figure 17:** Genomic DNA sequence of intron 5 of the IL-9R with a variation at nucleic acid 213 nt upstream from exon 6 where a T residue is changed to a C residue as indicated by the arrow.

DETAILED DESCRIPTION OF THE INVENTION

Applicants have resolved the needs in the art by elucidating an IL-9 pathway, and compositions that affect that pathway, which may be used in the treatment, diagnosis, and development of methods to identify agents to prevent or treat atopic asthma and related disorders.

Asthma encompasses inflammatory disorders of the airways with reversible airflow obstruction. Atopic allergy refers to atopy, and related disorders including asthma, bronchial hyperresponsiveness (BHR), rhinitis, urticaria, allergic inflammatory disorders of the bowel, and various forms of eczema. Atopy is a hypersensitivity to environmental allergens expressed as the elevation of serum total IgE or abnormal skin test responses to allergens as compared to controls. BHR refers to bronchial hyperresponsiveness, a heightened bronchoconstrictor response to a variety of stimuli.

By analyzing the DNA of individuals that exhibit atopic allergy and asthma-related disorders, applicants have identified polymorphisms in the IL-9 receptor (IL-9R) gene that may correlate with the expression of asthma. The IL-9 receptor gene (also known as Asthma Associated Factor 2 or AAF2) refers to the genetic locus of interleukin-9 receptor, a cytokine receptor associated with a variety of functions involving the regulation of human myeloid and lymphoid systems. The human IL-9 receptor gene of the present invention is found in the subtelomeric region of the XY chromosomes.

By polymorphism, applicants mean a change in a specific DNA sequence, termed a "locus," from the prevailing sequence. In general, a locus is defined as polymorphic when artisans have identified two or more alleles encompassing that locus and the least common allele exists at a frequency of 1% or more.

Specific amplification of the authentic IL-9R (gene encoding for the biologically functional protein located in the XYq pseudoautosomal region) using standard primer design was not possible because IL-9R has four highly homologous (>90% nucleotide identity), non-processed pseudogenes at other loci in the human genome (chromosome 9, 10, 16, 18). Because of the high identity of these other genes, genomic PCR amplification using standard primer design resulted in co-amplification of all genes, thus making sequence analysis of the authentic gene equivocal. In order to study authentic IL-9R structure as it may relate to predisposition to disease such as asthma, discussed in this application, or other diseases such as cancer (Renauld, et al., Oncogene, 9:1327-1332, 1994; Gruss, et al., Cancer Res., 52:1026-1031, 1992), applicants have designed specific amplimers. The specific primers were found to be authentic for IL-9R amplification with no amplification of the 4 pseudogenes. The primer sequences are shown in Example 2 and their specificity is demonstrated in Figure 13.

Applicants have also amplified, by RT-PCR, the entire coding region of the IL-9 receptor cDNA using RNA extracted from PBMCs (peripheral blood

mononuclear cells) purified from 50 donors. Fig. 1 illustrates the most frequent variations found in 50 individuals analyzed. Exon 3, 4, 5, 6 and 8 were affected by aberrant splicing events in samples where full-length cDNAs could also be cloned. Some transcripts showed complete deletion of exon 3, which causes a frameshift creating a stop codon after a stretch of 79 unrelated residues. In the case of deletion of exon 4, a frameshift is also generated and the first codon in exon 5 is converted to a stop codon. In some other cDNAs, exon 5 presented partial deletion of the first 5 or 29 nucleotides, both deletions leading to frameshifts resulting in early stop codons within exon 5. Hence, in all instances, the putative truncated protein would lack most of the extracellular domain as well as all the transmembrane and cytoplasmic domains. If secreted, these forms might function as soluble receptors. Finally, the first three nucleotides of exon 6, corresponding to codon 173, were frequently found spliced out, resulting in deletion of the glutamine at this codon with no other changes in the remaining protein sequence. This splice variant is possibly related to a variant found in intron 5 of the genomic DNA (SEQ ID NO 24) which would increase the frequency of the splice variant (Figure 17 and Example 12).

Applicants have also found allelic variations limited to the coding sequence of exon 9. Polymorphisms involving codon 310 and 410 have been previously disclosed.^{29, 30} (Kermouni, A., et al., Genomics, 371-382 (1995)). Codon 310 encodes for either arginine or glycine, depending on whether the first nucleotide at that codon is an adenine or a guanidine, respectively. At codon 410 (from hereon termed "410+n") begins a stretch of either 8 or 9 AGC trinucleotides repeats which would be translated in 8 or 9 serines, respectively.

Applicants have found a new polymorphism at codon 344. Here, the second nucleotide is either adenine or guanidine, the two possible residues encoded by this codon being histidine or arginine, respectively. Moreover, a correspondence between codon 344 and 410+n was observed wherein arginine at codon 344 is consistently found with 8 serines at codon 410+n and

histidine at codon 344 is found with 9 serines. The human IL-9 receptor cDNA originally cloned from a human megakaryoblastic leukemic cell line, Mo7e, presented 9 serines at codon 410+n and, unlike applicants' clones, an arginine at codon 344.²⁹ Another megakaryoblastic leukemic cell line UT-7 has been reported to carry the same arginine/9-serines allele.³⁰ Applicants cloned 16 cDNAs from Mo7e cell line and found that 6 had 8 serines at codon 410+n and arginine at codon 344. The remaining ten clones presented the published sequence. Applicants also genotyped the human acute myelogenous leukemia cell line KG-1 and found that it was histidine/9-serines homozygous.

These DNA molecules and corresponding RNA are isolated using techniques that are standard in the art, such as Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985). By isolated, applicants mean that the DNA is free of at least some of the contaminants associated with the nucleic acid or polypeptides occurring in a natural environment.

The invention also includes the proteins encoded by these nucleic acid sequences. The invention further includes fragments of the molecules. By fragments, applicants mean portions of the nucleic acid sequence that maintain the function of the full sequence. As would be known in the art, fragments result from deletions, additions, substitutions and/or modifications.

The source of the IL-9 receptor variants of the invention is human. Alternatively, the DNA or fragment thereof may be synthesized using methods known in the art. It is also possible to produce the compound by genetic engineering techniques, by constructing DNA by any accepted technique, cloning the DNA in an expression vehicle and transfecting the vehicle into a cell which will express the compound. See, for example, the methods set forth in Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985).

The demonstration of variant IL-9 receptor sequences which may be associated with atopic allergy and an asthma-like phenotype, and others which

may be associated with the lack of an asthma-like phenotype, provides methods of diagnosing susceptibility to atopic asthma and related disorders. Certain variants can produce soluble receptors which can be used for treating these disorders.

5 A receptor is a soluble or membrane-bound component that recognizes and binds to molecules, and the IL-9 receptor of the invention is the component that recognizes and binds to IL-9. The functions of the IL-9 receptor consist of binding to IL-9 or an IL-9-like molecule and propagating its regulatory signal in specific cells.^{29,30,34,35} Human IL-9 has been shown to cause phosphorylation
10 of the IL-9 receptor itself and the activation of proteins of the Jak-Stat pathway, Jak1, Stat1, Stat3, Stat5, and Irs2, upon binding the human IL-9 receptor (Demoulin, J-B., et al., Molecular and Cellular Biology, p. 4710-4716, Sept. 1996). Applicants have examined whether IL-9R or its variants showed any bias in the activation of these proteins and extended the analysis to Jak3 and
15 Irs1. It was determined that all of the proteins of the pathway including Jak3 and Irs1 were phosphorylated by IL-9R activation. It was also determined that IL-9R variants with changes at codons 310, 344 and 410+n provided the same up-regulation as wild type IL-9R. Therefore, one aspect of the invention is therapeutics for the treatment of atopic asthma which inhibit interactions in the
20 Jak-Stat pathway.

Unlike the wild type receptor and the other tested variants, the Δ Q173 variant could not activate any proteins in the Jak-Stat pathway (Figure 15). In addition, the Δ Q173 variant could not support cellular proliferation upon IL-9 stimulation (Figure 16). Therefore, individuals who express the Δ Q173 variant
25 are less likely to be susceptible to atopic asthma and related disorders. One aspect of the invention, therefore, is therapeutics that increase the expression of the Δ Q173 splice variant for the treatment of atopic asthma and related disorders.

One diagnostic embodiment involves the recognition of variations in the DNA
30 sequence of the IL-9 receptor gene or transcript. One method involves the use

of a nucleic acid molecule (also known as a probe) having a sequence complementary to the IL-9 receptors of the invention under sufficient hybridizing conditions, as would be understood by those in the art. In one embodiment, the nucleic acid molecule will bind specifically to the codon for Arg344 of the mature IL-9 receptor protein, or to His344, and in another embodiment will bind to both Arg344 and to His344. In yet another embodiment, it will bind to the codon for Gln 173. These methods may also be used to recognize other variants of the IL-9 receptor. Another method of recognizing DNA sequence variation associated with these disorders is direct DNA sequence analysis by multiple methods well known in the art.⁴⁴ Another embodiment involves the detection of DNA sequence variation in the IL-9 receptor gene associated with these disorders.⁴⁰⁻⁴⁴ These include the polymerase chain reaction, restriction fragment length polymorphism (RFLP) analysis, and single-stranded conformational analysis. In a preferred embodiment, applicants provide specifically for a method to recognize, on a genetic level, the polymorphism in IL-9 receptor associated with the His344 and Arg344 alleles using an ASO PCR. In other embodiments, the ligation chain reaction can be used to distinguish these alleles of IL-9 receptor genes.

The present invention also includes methods for the identification of antagonists of IL-9 and its receptor. Antagonists are compounds that are themselves devoid of pharmacological activity, but cause effects by preventing the action of an agonist. To identify an antagonist of the invention, one may test for competitive binding with a known agonist or for down-regulation of IL-9-like functions as described herein and in the cited literature.^{2,22-35}

Specific assays may be used to screen for pharmaceuticals useful in treating atopic allergy based on IL-9 receptor's known role on the proliferation of T lymphocytes, IgE synthesis and release from mast cells.^{29,30,33-35} Another assay involves the ability of human IL-9 receptor to specifically induce the rapid and transient tyrosine phosphorylation of multiple proteins in Mo7e cells.³⁴ Because this response is dependent upon the expression and

activation of the IL-9 receptor, it represents a simple method or assay for the characterization of potentially valuable compounds. The tyrosine phosphorylation of Stat3 transcriptional factor appears to be specifically related to the functions of the IL-9 receptor,³⁵ and this response represents a simple method or assay for the characterization of compounds within the invention. Still another method to characterize the function of the IL-9 receptor involves the use of the well known murine TS1 clone transfected with a human receptor which can be used to assess human IL-9 function with a cellular proliferation assay.²⁹ These methods can be used to identify antagonists of the IL-9 receptor.

In a further embodiment, the invention includes the down-regulation of IL-9 expression or function by administering soluble IL-9 receptor molecules that bind IL-9. Applicants and Renaud, et al.²⁹ have shown the existence of a soluble form of the IL-9 receptor. This molecule can be used to prevent the binding of IL-9 to cell-bound receptor and act as an antagonist of IL-9. Soluble receptors have been used to bind cytokines or other ligands to regulate their function.⁴⁵ A soluble receptor is a form of a membrane-bound receptor that occurs in solution, or outside of the membrane. Soluble receptors may occur because the segment of the molecule which commonly associates with the membrane is absent. This segment is commonly referred to in the art as the transmembrane domain of the gene, or membrane-binding segment of the protein. Thus, in one embodiment of the invention, a soluble receptor may represent a fragment or an analog of a membrane-bound receptor.

Applicants have identified three splice variants of the human IL-9 receptor that result in the production of proteins that could act as soluble receptors. One splice variant resulted in the deletion of exon 4 which introduced a frame-shift resulting in a stop codon as the first codon of exon 5. This variant would produce a peptide of about 45 residues that contains an epitope reactive with antibodies that block the IL-9/IL-9R interaction. The other two variants contain deletions in exon 5 that will produce premature stop codons early in the exon,

but, in these cases, without the deletion of exon 4. These variants would produce a protein of about 100 residues also containing the epitope recognized by blocking antibody.

5 Soluble IL-9 receptors may be used to screen for potential therapeutics, including antagonist useful in treating atopic asthma and related disorders. For example, screening for peptides and single-chain antibodies using phage display could be facilitated using a soluble receptor. Phage that bind to the soluble receptor can be isolated and the molecule identified by affinity capture of the receptor and bound phage. In addition, compound screenings for
10 agents useful in treating atopic asthma and related disorders can incorporate a soluble receptor and ligand that bind in the absence of an antagonist. Detection of the ligand and receptor interaction occurs because of the proximity of these molecules. Antagonists are recognized by inhibiting these interactions.

15 In addition, the invention includes pharmaceutical compositions comprising the compounds of the invention together with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
20 Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectionable solutions. Suitable pharmaceutical carriers are described in Martin, E.W., Remington's Pharmaceutical Sciences

25

The compounds used in the method of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and similar considerations.

Topical administration may be used. Any common topical formation such as a solution, suspension, gel, ointment, or salve and the like may be employed. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's
5 Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pa. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form. In a preferred embodiment, the compounds of this invention may be administered by inhalation. For inhalation therapy, the compound may be in a solution useful for administration by
10 metered dose inhalers, or in a form suitable for a dry powder inhaler.

The active ingredient may be administered in pharmaceutical compositions adapted for systemic administration. As is known, if a drug is to be a administered systemically, it may be confected as a powder, pill, tablet or the like, or as a syrup or elixir for oral administration. For intravenous,
15 intraperitoneal or intralesional administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as an extended release formulation for deposit under the skin or intermuscular injection.

20 An effective amount is that amount which will down-regulate the functions controlled by IL-9 receptor. A given effective amount will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given effective amount will be best determined at the time and place through routine
25 experimentation. It is anticipated, however, that in the treatment of asthma and related disorders in accordance with the present invention, a formulation containing between 0.001 and 5 percent by weight, preferably about 0.01 to 1%, will usually constitute a therapeutically effective amount. When administered systemically, an amount between 0.01 and 100 mg per kg body

weight per day, but preferably about 0.1 to 10 mg/kg, will affect a therapeutic result in most instances.

Applicants also provide for a method to screen for the compounds that down-regulate the functions controlled by the IL-9 receptor. One may determine whether the functions expressed by IL-9 receptor are down-regulated using techniques standard in the art.^{29,30,34,35} In a specific embodiment, applicants provide for a method of identifying compounds with functions comparable to IL-9. In one embodiment, the functions of IL-9 receptor may be assessed *in vitro*. As is known to those in the art, human IL-9 receptor activation specifically induces the rapid and transient tyrosine phosphorylation of multiple proteins in cells responsive to IL-9. The tyrosine phosphorylation of Stat3 transcriptional factor appears to be specifically related to the actions of the IL-9 pathway. Another method to characterize the function of IL-9 and IL-9-like molecules depends on the "stable expression" of the IL-9 receptors in murine TS1 clones or TF1 clones, which do not normally express human receptor. These transfectants can be used to assess human IL-9 receptor function with a cellular proliferation assay.²⁹

The invention also includes a simple screening assay for saturable and specific ligand binding based on cell lines that express the IL-9 receptor variants.^{23,29} The IL-9 receptor is expressed in a wide variety of cell types, including K562, C8166-45, KG-1 transfected with the human IL-9 receptors, B cells, T cells, mast cells, HL60, HL60-clone 5, TS1 transfected with the human IL-9 receptors, 32D transfected with the human IL-9 receptors, neutrophils, megakaryocytes (UT-7 cells),³⁰ the human megakaryoblastic leukemia cell line Mo7e³⁴, TF1,²⁹ macrophages, eosinophiles, fetal thymocytes, the human kidney cell line 293,³⁰ and murine 32D and embryonic hippocampal progenitor cell lines.^{23,29,30}

The practice of the present invention will employ the conventional terms and techniques of molecular biology, pharmacology, immunology, and biochemistry that are within the ordinary skill of those in the art. See, for example,

Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, or Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc.

Nonetheless, we offer the following basic background information. The body's genetic material, or DNA, is arranged on 46 chromosomes, which each comprises two arms joined by a centromere. Each chromosome is divided into segments designated p or q. The symbol p is used to identify the short arm of a chromosome, as measured from the centromere to the nearest telomere. The long arm of a chromosome is designated by the symbol q. Location on a chromosome is provided by the chromosome's number (i.e., chromosome 5) as well as the coordinates of the p or q region (i.e., q31-q33). In addition, the body bears the sex chromosomes, X and Y. During meiosis, the X and Y chromosomes exchange DNA sequence information in areas known as the pseudoautosomal regions.

DNA, deoxyribonucleic acid, consists of two complementary strands of nucleotides, which include the four different base compounds, adenine (A), thymine (T), cytosine (C), and guanine (G). A of one strand bonds with T of the other strand while C of one strand bonds to G of the other to form complementary "base pairs," each pair having one base in each strand.

A sequential grouping of three nucleotides (a "codon") codes for one amino acid. Thus, for example, the three nucleotides CAG code for the amino acid Glutamine. The 20 naturally occurring amino acids, and their one-letter codes, are as follows:

Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic Acid	Asp	D
Asparagine or		
Aspartic acid	Asx	B
Cysteine	Cys	C

23

	Glutamine	Gln	Q
	Glutamine Acid	Glu	E
	Glutamine or		
	Glutamic acid	Glx	Z
5	Glycine	Gly	G
	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
10	Methionine	Met	M
	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
15	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valine	Val	V

Amino acids comprise proteins. Amino acids may be hydrophilic, i.e.,
 displaying an affinity for water, or hydrophobic, i.e., having an aversion to
 20 water. Thus, the amino acids designated as G, A, V, L, I, P, F, Y, W, C and M
 are hydrophobic and the amino acids designated as S, Q, K, R, H, D, E, N and
 T are hydrophilic. In general, the hydrophilic or hydrophobic nature of amino
 acids affects the folding of a peptide chain and, consequently, the three-
 dimensional structure of a protein.

25 DNA is related to protein as follows:

genomic DNA ----> mRNA ----> protein

↑

↓

cDNA

Genomic DNA comprises all the DNA sequences found in an organism's cell. It is "transcribed" into messenger RNA ("mRNA"). Complementary DNA ("cDNA") is a complementary copy of mRNA made by reverse transcription of mRNA. Unlike genomic DNA, both mRNA and cDNA contain only the protein-encoding or polypeptide-encoding regions of the DNA, the so-called "exons." Genomic DNA may also include "introns," which do not encode proteins.

In fact, eukaryotic genes are discontinuous with proteins encoded by them, consisting of exons interrupted by introns. After transcription into RNA, the introns are removed by splicing to generate the mature messenger RNA (mRNA). The splice points between exons are typically determined by consensus sequences that act as signals for the splicing process. Splicing consists of a deletion of the intron from the primary RNA transcript and a joining or fusion of the ends of the remaining RNA on either side of the excised intron. Presence or absence of introns, the composition of introns, and number of introns per gene, may vary among strains of the same species, and among species having the same basic functional gene. Although, in most cases, introns are assumed to be nonessential and benign, their categorization is not absolute. For example, an intron of one gene can represent an exon of another. In some cases, alternate or different patterns of splicing can generate different proteins from the same single stretch of DNA. In fact, structural features of introns and the underlying splicing mechanisms form the basis for classification of different kinds of introns.

As to the exons, these can correspond to discrete domains or motifs as, for example, functional domains, folding regions, or structural elements of a protein; or to short polypeptide sequences, such as reverse turns, loops, glycosylation signals and other signal sequences, or unstructured polypeptide linker regions. The exon modules of the present combinatorial method can comprise nucleic acid sequences corresponding to naturally occurring exon

sequences or naturally occurring exon sequences which have been mutated (e.g., point mutations, truncations, fusions).

Returning now to the manipulation of DNA, DNA can be cut, spliced, and otherwise manipulated using "restriction enzymes" that cut DNA at certain known sites and DNA ligases that join DNA. Such techniques are well known to those of ordinary skill in the art, as set forth in texts such as Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1985) or Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994).

DNA of a specific size and sequence can then be inserted into a "replicon," which is any genetic element, such as a plasmid, cosmid, or virus, that is capable of replication under its own control. A "recombinant vector" or "expression vector" is a replicon into which a DNA segment is inserted so as to allow for expression of the DNA; i.e., production of the protein encoded by the DNA. Expression vectors may be constructed in the laboratory, obtained from other laboratories, or purchased from commercial sources.

The recombinant vector (known by various terms in the art) may be introduced into a host by a process generically known as "transformation." Transformation means the transfer of an exogenous DNA segment by any of a number of methods, including infection, direct uptake, transduction, F-mating, microinjection, or electroporation into a host cell.

Unicellular host cells, known variously as recombinant host cells, cells, and cell culture, include bacteria, yeast, insect cells, plant cells, mammalian cells and human cells. In particularly preferred embodiments, the host cells include *E.coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, Yeast, CHO, R1-1, B-W, LH, COS-J, COS-7, BSC1, BSC40, BMT10, and S69 cells. Yeast cells especially include *Saccharomyces*, *Pichia*, *Candida*, *Hansenula*, and *Torulopsis*.

As those skilled in the art recognize, the expression of the DNA segment by the host cell requires the appropriate regulatory sequences or elements. The regulatory sequences vary according to the host cell employed, but include, for

example, in prokaryotes, a promoter, ribosomal binding site, and/or a transcription termination site. In eukaryotes, such regulatory sequences include a promoter and/or a transcription termination site. As those in the art well recognize, expression of the polypeptide may be enhanced, i.e., increased over the standard levels, by careful selection and placement of these regulatory sequences.

In other embodiments, promoters that may be used include the human cytomegalovirus (CMV) promoter, tetracycline-inducible promoter, simian virus (SV40) promoter, moloney murine leukemia virus long terminal repeat (LTR) promoter, glucocorticoid inducible murine mammary tumor virus (MMTV) promoter, herpes thymidine kinase promoter, murine and human-actin promoters, HTLV1 and HIV IL-9 5' flanking region, human and mouse IL-9 receptor 5' flanking region, bacterial tac promoter and *Drosophila* heat shock protein scaffold attachment region (SAR) enhancer elements.

The DNA may be expressed as a polypeptide of any length such as peptides, oligopeptides, and proteins. Polypeptides also include translational modifications such as glycosylations, acetylations, phosphorylations, and the like.

Another molecular biologic technique of interest to the present invention is "linkage analysis." Linkage analysis is an analytic method used to identify the chromosome or chromosomal region that correlates with a trait or disorder.⁴⁷ Chromosomes are the basic units of inheritance on which genes are organized. In addition to genes, artisans have identified "DNA markers" on chromosomes. DNA markers are known sequences of DNA whose identity and sequence can be readily determined. Linkage analysis methodology has been applied to the mapping of disease genes, for example, genes relating to susceptibility to asthma, to specific chromosomes.^{47,48}

Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed. It is intended that the specification and examples be considered exemplary only with a

5 true scope of the invention being indicated by the claims.

Having provided this background information, applicants now describe preferred aspects of the invention.

EXAMPLE 1

10 Identification of IL-9 receptor transcript polymorphisms

A population of 52 individuals was ascertained randomly with respect to asthma and atopy from the Philadelphia, Pennsylvania, area. Total serum IgE were assayed by enzyme-linked immunosorbent assay (ELISA, Genzyme, Cambridge, Massachusetts).

15 To assess the structural forms of the human IL-9 receptor cDNA, PBMCs from these 52 unrelated donors were isolated and cultured in the presence of PHA and PMA (described in Example 4). Previous data from applicants' laboratory demonstrated the kinetics of expression for IL-9 receptor message in primary cultures peak at day 6 after mitogen stimulation. Applicants cultured
20 the cells, therefore, for 6 days at which time the cells were harvested and their RNA and DNA were isolated as described in Example 5.

RNAs were reverse transcribed and amplified by PCR using primers specific for full-length IL-9 receptor cDNA as described in Example 5. Amplification products from each individual were cloned into the TA PCR cloning vector and
25 ten clones containing the expected inserts (as determined by digestion and gel electrophoresis) were sequenced in their entirety and analyzed for structural or sequence variation.

Seven major variants were identified from the above screen. These cDNAs represent a codon 173 deletion, an exon 4 deletion, two separate deletions in
30 exon 5, an exon 8 deletion, and a full-length cDNA containing an ARG-to-HIS

change at codon 344 of the mature protein . Additional variants exist on each of these genetic backgrounds. The Arg allele is associated with 8 Ser/4 Asn repeats and 7 Ser/4 Asn repeats; the His allele is associated with 9 Ser/4 Asn repeats, 9 Ser/3 Asn repeats, and 10 Ser/2 Asn. All of these variants are depicted in Figure 1.

Variants were cloned into the eukaryotic expression vector pCEP4 (Clontech) which contains a CMV promoter that drives the expression of the cloned cDNA followed by an SV40 polyadenylation signal. The vector also contains a hygromycin B resistance gene which is used for selection of eukaryotic cells containing the vector and presumably expressing the cloned cDNA under control of the CMV promoter. Recombinant plasmids were analyzed by sequence and those plasmids containing the correct cDNA inserts were transfected into eukaryotic recipient cells such as the Syrian hamster fibroblast TK-ts13, the human glioblastoma T98G, the human myeloid leukemia line TF-1, and the murine myeloid precursor cell line 32D as described in Example 3. Function was biologically assessed as a response to the IL-9 ligand in growth and/or apoptosis (Examples 7 and 10).

Experiments in which the full-length IL-9 receptor cDNAs containing the ARG or HIS variants were performed are the TK-ts13 hamster fibroblasts or the human T98G glioblastoma cells. Cells were transfected and analyzed 48 hours later by Western blot and *in situ* staining using human specific carboxy terminal antibodies (Santa Cruz) (Example 8). *In situ* analysis demonstrated that both forms of receptor appeared to be expressed in both the hamster and human lines (Figures 11 and 12). Interestingly, while Western blots of both forms appeared to be expressed at equal levels in both the human and hamster lines, a differential migration pattern appeared between the ARG and HIS receptor forms in the TS1 cell line (Figure 12) which suggests a differential post-translational modification such as glycosylation, phosphorylation, etc. This biochemical difference may be the mechanism by which the altered function results in altered phenotype.

The frequency of the various substitutions were used as an unbiased estimate of the prevalence of each variant in the general population. Genotype was compared to phenotype assessed by questionnaire. A diagnosis of allergy and asthma was determined by a physician reviewing the questionnaires. Individuals homozygous for the Arg344 alleles were significantly less likely to demonstrate evidence for allergy and asthma when compared to heterozygotes or homozygous His344 (Figure 9).

EXAMPLE 2

Genomic analysis of the IL-9 receptor genes.

In order to perform genomic analyses of allergic and/or asthmatic individuals, the following strategy was designed to create PCR-specific primers for the authentic IL-9 receptor genes located on the X/Y pseudoautosomal regions and exclude the highly conserved IL-9 receptor pseudogenes located on chromosomes 9,10,16,and 18. First, sequence alignments were performed between the two published pseudogenes and the genomic sequence of the IL-9 receptor genes. Primers were then initially designed in divergent regions between the authentic genes and the pseudogenes, and then analyzed by PCR using single chromosome-specific hybrids derived from Coreill DNA Repository (Camden, NJ). If the primers only produce correct sized products from X and Y hybrids, they were then optimized for robust amplification. In several cases, primers directed to the divergent regions were not XY specific; therefore, applicants introduced additional base changes in the particular primer to increase the number of mismatches higher against the pseudogenes as compared to the IL-9 receptor gene sequence. Table 1 contains the sequence of the primers and optimal annealing temperatures for XY-specific amplification. The specificity of these primers for XY amplification are demonstrated in Figure 13.

Table 1: X/Y Specific Amplimers of IL-9 Receptor

EXON	SENSE PRIMER	ANTISENSE PRIMER	TEMP	SIZE
2	5'- GCA GGT GGG GAC CCA TG -3' (SEQ ID NO 8)	5'- AGG CTT GAC ATC GGA CAA C -3' (SEQ ID NO 9)	68°	300 bp
3	5'- CTG GCC TGA AGT ACT TAC C -3' (SEQ ID NO 10)	5'- CTG CTT CAA TCC TGG GGA A -3'(SEQ ID NO 11)	62°	222 bp
4	5'- GTG AGT TCC CCA GGA TTG A -3' (SEQ ID NO 12)	5'- CAA GGC CCT GCT CCA AA -3' (SEQ ID NO 13)	64°	335 bp
5	5'- TGG GGC TTC AGC CTC ACA TG -3' (SEQ ID NO 14)	5'- TAT GTA GAG TGG GGA GTC TA -3' (SEQ ID NO 15)	62°	259 bp
6	5'- TGT ATT CTC GAG GGC TGA G -3' (SEQ ID NO 16)	5'- TGA GGT GAA CAG GGG AGA A -3' (SEQ ID NO 17)	62°	337 bp
7	5'- CCC TGG GCC CTT CAT GT -3' (SEQ ID NO 18)	5'- ACA AGG GCG GCC TTT GAT -3' (SEQ ID NO 19)	60°	262 bp
8	5'- AGG GAC GAG GTG GGC GGA C -3' (SEQ ID NO 20)	5'- CCT GCC CCC CAT GTT CTT -3' (SEQ ID NO 21)	58°	376 bp
9	5'- ATG CTA CCT GAG CCC TTC C -3' (SEQ ID NO 22)	5'- GGA CAT GAT GCA TCT GGC G -3' (SEQ ID NO 23)	62°	664 bp

These primers represent a novel method for analyzing DNA sequence variation in these genes which can be used for diagnosis of susceptibility or resistance to atopic asthma and related disorders.

5 Using this technology, each exon was examined by DNA sequence analyses for individuals in applicants' populations to detect sequence variation in the IL-9 receptor gene.⁴⁴ Sequence polymorphisms were distinguished from artifact by repeated analyses. An association of the receptor variants with the allergic phenotypes is set forth in Figure 9. The sequence of the receptor alleles is set forth in Figures 1-8.

10

5

EXAMPLE 3

IL-9 receptor expression and ligand binding assay

10

15

20

25

Purified recombinant IL-9 and compounds potentially resembling IL-9 in structure or function are fluorescently labeled to high specific activity by using commercially available techniques according to the supplier's recommendations (Pierce). Human Mo7e and murine 32D cells are grown and resuspended at 37°C in 0.8ml of Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) fetal bovine serum, 50 mM 2-mercaptoethanol, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine or RPMI supplemented with 10% (vol/vol) fetal bovine serum, 50 mM 2-mercaptoethanol, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine, respectively. TF1.1 (TF1 cells lacking human IL-9 receptors), T98G, TK⁻, and murine 32D cells, (Examples 7 and 10) were used as is or after transfection with the human IL-9 receptor constructs as described below. Plasmid DNA containing one of the full-length or truncated forms of IL-9 receptors were cloned into pCEP4 plasmid (Clontech) and purified by centrifugation through Qiagen columns (Qiagen). Plasmid DNA (50 micrograms) was added to the cells in 0.4 cm cuvettes just before electroporation. After a double electric pulse (750V/74 ohms/40 microfarads and 100 V/74 ohms/2100 microfarads), the cells are immediately diluted in fresh medium supplemented with IL-9.

Stable transfected cells were generated after 14 days of selection with hygromycin B (400 µg/ml to 1.6 mg/ml). Hygromycin-resistant clones were

5 analyzed for IL-9 receptor expression by Western blots and *in situ* staining as described in Example 8.

Cellular receptor binding is visualized directly in real time with fluorescence microscopy. Binding and internalization is followed over time in control cells (not transfected), and with cells transfected with each of the known IL-9 receptor
10 variants. An excess of unlabeled ligand or blocking antibody is used in parallel experiments to demonstrate specific binding.

Soluble IL-9 receptor including amino acids 44 to 270 with or without a HA ditag is also incubated with different forms of human labeled recombinant IL-9. Varying amounts of FLAG-tagged (IBI) ligand are incubated in PBS at room temperature
15 for 30 minutes with 0.5 µg of soluble receptor. EBC buffer (50 mM Tris pH 7.5; 0.1 M NaCl; 0.5% NP40) is added (300 µl) along with 1 µg of anti-HA antibody or anti-FLAG monoclonal antibody (IBI) and incubated for 1 hour on ice. Forty microliters of protein A sepharoseTM solution were added to each sample and mixed for 1 hour at 4°C. Samples were centrifuged for 1 minute 11,000 X G and pellets
20 were washed 4 times with 500 µl of EBC. Pellets were dissolved in 26 µl of 2X SDS buffer, boiled for 4 minutes, and electrophoresed through an 18% SDS polyacrylamide gel. Western blots were probed with an anti-IL-9 receptor antibody (Santa Cruz Inc.) or anti-FLAG monoclonal antibody (IBI) against FLAG-tagged rhIL-9. Therapeutic candidates are assessed by measuring the
25 antagonism of ligand binding. Receptor expression is shown in Figures 11 and 14.

5

EXAMPLE 4

Cell Isolation and culture

Human peripheral blood mononuclear cells (PBMC) were isolated from healthy donors by density gradient centrifugation using endotoxin tested Ficoll-Paque PLUSTM according to the manufacturer (Pharmacia Biotech, AB Uppsala Sweden).
10 PBMC (5×10^6), mouse spleen cells (5×10^6), or 5×10^6 Mo7e cells were cultured in 7 ml of RPMI-1640 (Bethesda Research Labs (BRL), Bethesda, MD) supplemented to a final concentration of 10% with either isogenic human serum or heat-inactivated FBS. Cells were cultured for 24 hrs at 37°C either unstimulated, or stimulated with either PMA 5 µg/ml/ PHA 5 µg/ml, or PHA 5
15 µg/ml and rhIL2 50 ng/ml (R&D Systems, Minneapolis, MN).

EXAMPLE 5

DNA & RNA isolations, rtPCR, cloning, and sequencing of PCR products

Cytoplasmic RNA and genomic DNA were extracted after 6 days of mitogen
20 stimulation from cultured PBMCs, as described by Nicolaides and Stoeckert.⁴⁶ One µg of RNA from each source was denatured for >10 minutes at 70°C and then reverse transcribed(V+) into cDNA using 2.5 units of Superscript II reverseTM transcriptase (GIBCO, BRL), 1U/l RNase Inhibitor, 2.5 mM oligo d(T)16 primer, 1mM each of dATP, dCTP, dGTP, dTTP, 50 mM KCl, 10 mM Tris-HCL, pH 7.0,
25 25 mM MgCl₂ at 37°C for one hour. A mock reverse transcription reaction was used as a negative control.

5 One-twentieth of the rt reaction was used in PCR (50 μ l) containing 6.7 mM
MgCl₂, 16.6 mM (NH₄)₂SO₄, 67 mM Tris-HCl, pH 8.8, 10 mM 2-mercaptoethanol,
6% DMSO, 1.25 mM of each dNTP, 2.5U Amplitaq DNA polymerase, and 300 ng
of each of the oligonucleotides representing human cDNA IL-9 exon 2 (forward
5'-GCT GGA CCT TGG AGA GTG-3')(SEQ ID NO 1) and exon 9 (reverse 5'-GTC
10 TCA GAC AAG GGC TCC AG-3')(SEQ ID NO 2). The reaction mixture was
subjected to the following PCR conditions: 120 seconds at 95°C, then 35 cycles
at: 30 seconds at 94°C; 90 seconds at 58°C; 90 seconds at 72°C. Finally, the
reaction mixture was cycled one time for 15 minutes at 72°C for extension.

PCR products representing hIL-9 receptor cDNA were subjected to gel
15 electrophoresis through 1.5% agarose gels and visualized using ethidium bromide
staining. Products of a mock reverse transcriptase reaction, in which H₂O was
substituted for RNA, were used as a negative control amplification in all
experiments.

PCR products were subcloned into the TA Cloning vector (Invitrogen, San
20 Diego, CA). Amplification of the human cDNA gave a 1614 bp product. Plasmids
containing hIL-9 receptor cDNA inserts were isolated by conventional techniques
(Sambrook, J., et al. (1989) Molecular Cloning: A Laboratory Manual Cold Spring
Harbor Laboratory Press, New York). After amplification the DNA sequence
including and surrounding each insert was analyzed by sequencing (Sanger et al.,
25 1977, Proc. Natl. Acad. Sci. USA 74:5463) using fluorescent dideoxyterminators
and on an automated sequencer (ABI 377, Perkin Elmer) for determination of
PCR-induced or cloning-induced errors. hIL-9 receptor cDNA inserts without

5 cloning and/or polymerase-induced sequence errors were subcloned into expression vectors.

EXAMPLE 6

Cloning and expression of IL-9 receptor constructs *in vitro*

10 hIL-9 receptors were subcloned into the episomal eukaryotic expression vector pCEP4 (Clontech). Inserts were cloned as BamH1-XhoI fragments into the pCEP4 polylinker in the sense orientation to the CMV promoter using standard techniques (Figure 10). Constructs were expressed in cellular hosts as described.

15

EXAMPLE 7

Cellular assays using (Mo7e, 32D, TF1.1, TK^{ts}13, and T98G)

Cell lines were used to assess the function of variant IL-9 receptors and for the screening of compounds potentially useful in the treatment of atopic asthma. Compounds were tested for their ability to antagonize the anti-apoptotic or baseline proliferative response elicited by IL-9. Once a baseline anti-apoptotic or proliferative response was established in a given cell line, a statistically significant loss of response in assays repeated three times in triplicate was considered evidence for antagonism. A true antagonistic response was differentiated from cellular toxicity by direct observation, trypan blue staining (a technique well known to one of normal skill in the art), or loss of acid phosphatase activity. Specificity of antagonism is assessed for each compound by evaluating whether the activity is

20

25

5 demonstrated against other proliferative agents such as interleukin 3 or interleukin 4.

Recombinant IL-9 and compounds potentially resembling IL-9 in structure or function were purified and prepared for use in the appropriate media. Putative agonists and antagonists were prepared in water, saline, or DMSO and water.

10 Cells were used as is or after transfection with the IL-9 receptor constructs as described in Example 3. After 24 hrs of deprivation from growth factors, the cells were incubated without (control) or with variable amounts of purified IL-9 and compounds potentially resembling IL-9 in structure or function.

Cell proliferation was assayed using the Abacus Cell Proliferation Kit (Clontech, Palo Alto, CA) which determines the amount of intracellular acid phosphatase present as an indication of cell number. The substrate p-nitrophenyl phosphate (pNPP) was converted by acid phosphatase to p-nitrophenol, which was measured as an indicator of enzyme concentration. pNPP was added to each well and incubated at 37°C for one hour. 1N sodium hydroxide was then added to stop the enzymatic reaction, and the amount of p-nitrophenol was quantified using a Dynatech 2000 plate reader (Dynatech Laboratories, Chantilly, VA) at 410 nm wavelength. Standard curves that compare cell number with optical absorbance were used to determine the linear range of the assay. Assay results were only used when absorbance measurements are within the linear range of the assay.

25 Briefly, the assays were run with quadruplicate samples of cells in flat-bottom microtiter plates (150 or 200 microliter wells) with or without ligand for 72 to 96

5 hours at 37 degrees C. Acid phosphatase was used as a measure of the number of cells present. All experiments are repeated at least twice.

Apoptosis was assayed using the Annexin V kit as described by the supplier (Clontech) which determines dexamethasone-induced apoptosis by recognizing extracellular phosphatidylserine, an early marker for apoptosis. Apoptotic cell
10 number was scored by fluorescence microscopy as a percentage of Annexin V stained cells.

The Mo7e line is a human megakaryoblastic cell line, cultured in RPMI 1640 (GIBCO/BRL, Gaithersburg, MD), 20% Fetal Bovine Serum (Hyclone) and 10 ng/ml IL-3 (R&D Systems, Minneapolis, MN). The T98G line is a human
15 glioblastoma cell line grown in RPMI 1640 (GIBCO/BRL). The hamster fibroblast TK-ts13 line was also used as well as the murine 32D cell line, a murine myeloid precursor line, and both were cultured in RPMI 1640 (GIBCO/BRL) containing 10% fetal bovine serum (Hyclone) in addition 1 ng/ml m IL-3 was used with the 32
20 D cell lines. TF1.1 is a human myeloid leukemia line known to express the IL-2 receptor gamma subunit (confirmed by Western blots and rtPCR), but, in comparison to its predecessor (TF1), it no longer bears IL-9 receptor by rtPCR, immunostaining, and Western blot analyses. TF1.1 is cultured in RPMI 1640 (GIBCO/BRL) and 10% Fetal bovine serum (Hyclone). All the cell lines respond to multiple cytokines including IL-9. The cell lines were fed and reseeded at 2 X
25 10^5 cells/ml every 72 hours.

The cells were centrifuged for 10 minutes at 2000 rpm and resuspended in RPMI 1640 with 0.5% Bovine Serum Albumin (GIBCO/BRL, Gaithersburg, MD)

5 and insulin-transferrin-selenium (ITS) cofactors (GIBCO/BRL, Gaithersburg, MD). Cells were counted using a hemocytometer and diluted to a concentration of 1×10^5 cells/ml and plated in a 96-well microtiter plate. Each well contained 0.15 or 0.2 ml, giving a final concentration of 10 to 50 thousand cells per well depending on the cell. Mo7e cells were stimulated with 50 ng/ml Stem Cell Factor (SCF) (R&D Systems, Minneapolis, MN) alone, 50 ng/ml SCF plus 50 ng/ml IL-3 (R&D Systems, Minneapolis, MN), or 50 ng/ml SCF plus 50 ng/ml IL-9. A control was included which contained cells and basal media only. Serial dilutions of test compounds (i.e, recombinant IL-9 proteins, peptides, small molecules) were added to each test condition in triplicate. TF1.1 cells that were not transfected with IL-9 receptors were used as an independent control for response and nonspecific cytotoxicity. Cultures were incubated for 72-96 hours at 37°C in 5% CO₂.

EXAMPLE 8

20 *In situ* & Western analysis of exogenous IL-9 receptor in transfected cell lines

In situ staining of the IL-9 receptor was carried out as follows. Cells were grown on coverslips for 24 hours and then coverslips containing the adherent cells were washed twice in phosphate buffered saline solution containing calcium and magnesium(PBS) (Gibco/BRL). For intracellular staining of the IL-9 receptor, the cells were fixed in 4% paraformaldehyde/PBS plus 0.1% triton-XTM for 15 minutes at room temperature before treatment with anti-human IL-9 receptor antibody; for extracellular staining, cells were treated with antibody before fixation. The cells

5 were then washed twice in PBS and blocked with 7.5% BSA in dH₂O for 30
minutes at room temperature. PBS washed cells were then incubated with a 10
µg/ml solution of anti-human IL-9 receptor (polyclonal antibody directed against
the carboxy terminus of the IL-9 receptor) in 1% BSA/PBS for 1 hour at room
temperature. Cells were washed three times in PBS and then incubated in 10
10 µg/ml solution of an anti-rabbit rhodamine-conjugated antibody in 1% BSA/PBS
for 30 minutes at room temperature. Cells were then washed three times in PBS
and counter- stained using 1 µg/ml DAPI for 1 minute at room temperature. Cells
were washed three times in dH₂O and fixed to a microscope slide and analyzed
by fluorescence microscopy. The results for the transfected COS7 cells are
15 shown in Figure 14.

Western blots were performed on protein lysates obtained from direct lysis of
cell extracts in 0.5% lysis buffer (Tris 50mM, NaCl 150 mM, NP40), 1 mM DTT
and protease inhibitors) and boiled for 5 minutes. Samples were electrophoresed
on 4-20% tris-glycine SDS gels (Novex) in tris-glycine running buffer. Proteins
20 were then transferred to nitrocellulose by electroblot using the Trans Blot II
apparatus (Bio Rad). After transfer, the membrane was blocked in TBS-T ((20
mM Tris, 137 mM NaCl, pH 7.6) plus 0.05% TweenTM 20) plus 5% blotto for 1 hour
room temperature. Blots were then probed using a polyclonal antibody directed
to the carboxy terminus of the IL-9 receptor (1 µg/ml) in TBS-T for 1 hour. Blots
25 were then washed three times in TBS-T for 10 minutes and probed using a
secondary anti-rabbit-horse radish peroxidase conjugated antibody (1:10,000) in
TBS-T for 30 minutes. Blots were washed as above and then incubated with

5 Luminol/enhancer solution (Pierce), a chemiluminescent substrate, for 5 minutes at room temperature and then exposed to film for 1-60 seconds. See Figures 11 and 12.

10 EXAMPLE 9

Methods for the Authentic IL-9R Genomic Amplification

Specific amplification of the authentic IL-9R (gene encoding for the biologically functional protein located in the XYq pseudoautosomal region) using standard primer design was not possible because IL-9R has four highly homologous (>90% nucleotide identity), nonprocessed pseudogenes at other loci in the human genome (chromosome 9, 10, 16, 18). Because of the high identity of these other genes, genomic PCR amplification using standard primer design resulted in co-amplification of all genes, thus making sequence analysis of the authentic gene equivocal. In order to study authentic IL-9R structure as it may relate to predisposition to disease such as asthma, discussed in this application, or other diseases such as cancer (Renauld, et al., Oncogene, 9:1327-1332, 1994; Gruss, et al., Cancer Res., 52:1026-1031, 1992), specific amplimers were designed as follows:

Sequences of the IL-9R pseudogene and authentic genes were aligned using Mac Vector software. Intronic sequences surrounding each exon were then inspected for regions of diversity between the authentic gene and pseudogenes. Primers were then designed against these regions, and used to PCR amplify

5 human/rodent hybrid DNAs containing individual human chromosomes. Products
were run on 3% agarose gels and analyzed for authentic IL-9R amplification with
no amplification of the 4 pseudogenes. Specific PCR amplification conditions
were also optimized by varying annealing temperature and buffer conditions
(DMSO content 5-10%). In cases where amplification of pseudogenes still
10 occurred, nucleotide changes were entered into primer sequences to cause
greater divergence from the pseudogenes as compared to the authentic gene.
Primer sequences are shown in Example 2 and their specificity is demonstrated in
Figure 13.

15

EXAMPLE 10

Cell proliferation assay and cytokine stimulation

To determine growth response of TS1 cells expressing various forms of human
IL-9 receptor, cells were washed with PBS and resuspended in D-MEM, 10% fetal
bovine serum. 10^3 cells per well were seeded in triplicate in 96-well microplates
and, where appropriate, recombinant human IL-9 or murine IL-9 (R&D Systems,
20 Minneapolis, MN) was added at a final concentration of 5 ng/ml. Cell proliferation
was evaluated after 7 days using an acid phosphatase assay. Briefly, 50 μ l of a
buffer containing 0.1M sodium acetate (pH 5.5), 0.1% Triton X-100 and 10mM p-
nitrophenyl phosphate (Sigma 104 phosphatase substrate) was added per well.
25 The plate was incubated for 1-1/2 hours at room temperature, the reaction
stopped with 10 μ l/well of 1N sodium hydroxide and the absorbance was read on
a Dynatech Model MR600 at 410nm. To analyze tyrosine-phosphorylation of

5 proteins of the signal transduction cascade upon cytokine stimulation, TS1 cells
expressing various forms of human IL-9 receptor were washed with PBS,
resuspended in D-MEM, 0.5% bovine serum albumin, and incubated for 6 hours
at 37°C. Successively, 20×10^6 cells were treated for 5 minutes with either
human IL-9 or murine IL-9 (100 ng/ml) and immediately washed in cold PBS.
10 Cells were lysed in RIPA buffer as described in Example 11.

EXAMPLE 11

Immunoprecipitations, immunoblotting and antibodies

Typically, $20\text{-}50 \times 10^6$ cells were lysed in 1 ml of RIPA buffer (PBS containing
15 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM PMSF, 50mM sodium
fluoride, 1nM sodium orthovanadate, and 1x "Complete" protease inhibitors
mixture, Cat. No. 1697498 Boehringer Mannheim) and incubated for 45 minutes
on ice. Lysates were centrifuged for 20 minutes in an Eppendorf microcentrifuge
and the supernatant recovered and transferred to a fresh tube. For
20 immunoprecipitations, 1-5 μg of the antibody were added to the lysate and
incubated overnight at 4°C. 20 ml of Protein A+G agarose-conjugated beads
were added for 2 hrs followed by four washings using RIPA buffer. Beads were
resuspended in Laemmli buffer and boiled for 3 minutes before electrophoresis.
Proteins were transferred onto Immobilon-P membrane (Millipore) and detected
25 using a horseradish peroxidase-conjugated secondary antibody followed by a
chemiluminescence detection assay (Pierce). Specific antibodies for murine and
human IL-9 receptor (sc698), murine Jak1, Irs1, Irs2, Stat1, Stat2, Stat3, Stat4,

5 Stat5, and phosphotyrosine (PY) were purchased from Santa Cruz (Santa Cruz, CA). Anti-Jak3 and monoclonal anti-human IL-9 receptor MAB290 were purchased from Upstate Biotechnology and R&D Systems, respectively. Figure 15 demonstrates the activation of members of the Jak family via different variants of the human IL-9 receptor.

10

EXAMPLE 12

Identification of IL-9 receptor genomic polymorphisms

Genomic DNAs were isolated from PBMCs of volunteer donors as described (Nicolaidis and Stoeckert, Biotechniques 8:154-156, 1990). Sequence analysis of intron 5 of the human IL-9R gene was performed by PCR using primers of sequence ID NO 14 and sequence ID NO 17 which resulted in a product with the approximated molecular size of 1243 basepairs. Amplifications were carried out at 94°C for 30 seconds, 62°C for 1.5 minutes, 72°C for 1.5 minutes for 35 cycles in buffers described previously (Nicholaides et al., Genomics 30:195-206, 1995). Products were then purified and sequenced using a standard sequence protocol. Inspection of the sequences from intron 5 in multiple individuals found a nucleotide change at -213 nt upstream of exon 6 sequences which resulted in a thymidine (published sequence) to a cytosine nucleotide change. An example of this change is shown in figure 17.

25 While the invention has been described and illustrated herein by references to various specific materials, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and

- 5 procedures selected for that purpose. Numerous variations of such details can be implied as will be appreciated by those skilled in the art.

5 REFERENCES

1. Gergen PJ, and Weiss KB: The increasing problem of asthma in the United States. Am Rev Respir Dis 146:823-824, 1992.
2. Goodman and Gilman's The Pharmacologic Basis of Therapeutics, Seventh Edition, MacMillan Publishing Company, N.Y. USA, 1985.
- 10 3. Burrows B, Martinez FD, Halonen M, Barbee RA, and Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. New Eng J Med 320:271-277, 1989.
4. Clifford RD, Pugsley A, Radford M, and Holgate ST: Symptoms, atopy, and bronchial response to methacholine in parents with asthma and their
15 children. Arch Dis in Childhood 62:66-73, 1987.
5. Gergen PJ: The association of allergen skin test reactivity and respiratory disease among whites in the U.S. population. Arch Intern Med 151:487-492, 1991.
6. Burrows B, Sears MR, Flannery EM, Herbison GP, and Holdaway MD:
20 Relationship of bronchial responsiveness assessed by methacholine to serum IgE, lung function, symptoms, and diagnoses in 11-year-old New Zealand children. J Allergy Clin Immunol 90:376-385, 1992.
7. Johansson SGO, Bennich HH, and Berg T: The clinical significance of IgE. Prog Clin Immunol 1:1-25, 1972.
- 25 8. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, and Holdaway MD: Relation between airway responsiveness and serum IgE in

- 5 children with asthma and in apparently normal children New Engl J Med
325(15):1067-1071, 1991.
9. Halonen M, Stern D, Taussig LM, Wright A, Ray CG, and Martinez FD:
The predictive relationship between serum IgE levels at birth and subsequent
incidences of lower respiratory illnesses and eczema in infants. Am Rev Respir
10 Dis 146:666-670, 1992.
10. Marsh DG, Meyers DA, and Bias WB: The epidemiology and genetics of
atopic allergy. New Eng J Med 305:1551-1559, 1982.
11. Hopp RJ, Bewtra AK, Biven R, Nair NM, Townley RG. Bronchial reactivity
pattern in nonasthmatic parents of asthmatics. Ann Allergy 1988;61:184-186.
- 15 12. Hopp RJ, Townley RG, Biven RE, Bewtra AK, Nair NM. The presence of
airway reactivity before the development of asthma. Am Rev Respir Dis
1990;141:2-8.
13. Ackerman V, Marini M, Vittori E, et al. Detection of cytokines and their
cell sources in bronchial biopsy specimens from asthmatic patients: relationship
20 to atopic status, symptoms, and level of airway hyperresponsiveness. Chest
1994;105:687-696.
14. Hamid G, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5
in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87:1541-1546.
15. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in
25 asthma. Am Rev Respir Dis 1990;142:434-57.

- 5 16. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like
bronchoalveolar T lymphocyte population in atopic asthma. N Engl J Med
1992;326:298-304.
- 10 17. Robinson DS, Hamid Q, Ying S, et al. Prednisolone treatment in asthma
is associated with modulation of bronchoalveolar lavage cell interleukin-4,
interleukin-5, and interferon- γ cytokine gene expression. Am Rev Respir Dis
1993;148:401-406.
- 15 18. Robinson DS, Ying S, Bentley A, et al. Relationship among numbers of
bronchoalveolar lavage cells expressing messenger ribonucleic acid for
cytokines, asthma symptoms, and airway methacholine responsiveness in atopic
asthma. J Allergy Clin Immunol 1993;92:397-403.
19. O'Connor GT, Sparrow D, and Weiss ST: The role of allergy and
nonspecific BHR in the pathogenesis of COPD. Am Rev Respir Dis
140:225-252, 1989.
- 20 20. Cogswell JJ, Halliday DF, and Alexander JR: Respiratory infections in
the first year of life in children at the risk of developing atopy. Brit Med J
284:1011-1013, 1982.
21. Boushey HA, Holtzman MJ, Sheller JR, and Nadel JA: BHR. Am Rev
Respir Dis 121:389-413, 1980.
- 25 22. Renauld, J-C, Houssiau, F, Druez, C. Interleukin-9. Int Rev Exp
Pathology 1993;34A: 99-109.

- 5 23. Renauld, J-C, Kermouni, A, Vink, A, Louahed, J, Van Snick, J.
Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell
oncogenesis. J Leukoc Biol 1995;57:353-360.
24. Hultner, L, Moeller, J, Schmitt, E, Jager, G, Reisbach, G, Ring, J, Dormer,
P. Thiol-sensitive mast cell lines derived from mouse bone marrow respond to a
10 mast cell growth-enhancing activity different from both IL-3 and IL-4. J Immunol
1989;142:3440-3446.
25. Dugas, B, Renauld, J-C, Pene, J, Bonnefoy, J, Peti-Frere, C, Braquet, P,
Bousquet, J, Van Snick, J, Mencia-Huerta, JM. Interleukin-9 potentiates the
interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal
15 human B lymphocytes. Eur J Immunol 1993;23:1687-1692.
26. Petit-Frere, C, Dugas, B, Braquet, P, Mencia-Huerta, JM. Interleukin-9
potentiates the interleukin-4-induced IgE and IgG1 release from murine B
lymphocytes. Immunology 1993;79:146-151.
27. Behnke, JM, Wahid, FN, Grencis, RK, Else, KJ, Ben-Smith, AW, Goyal,
20 PK. Immunological relationships during primary infection with *Heligmosomoides*
polygyrus (*Nematospiroides dubius*): downregulation of specific cytokine
secretion (IL-9 and IL-10) correlates with poor mastocytosis and chronic survival
of adult worms. Parasite Immunol 1993;15:415-421.
28. Gessner, A, Blum, H, Rollinghoff, M. Differential regulation of IL-9
25 expression after infection with *Leishmania major* in susceptible and resistant
mice. Immunobiology 1993;189:419-435.

- 5 29. Renauld J-C, Druez C, Kermouni A, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci 89:5690-5694(1992).
30. Chang M-S, Engel G, Benedict C et al. Isolation and characterization of the Human interleukin-9 receptor gene. Blood 83:3199-3205(1994).
- 10 31. Renauld J-C, Goethals A, Houssiau F, et al. Human P40/IL-9. Expression in activated CD4+ T cells, Genomic Organization, and Comparison with the Mouse Gene. J Immunol 144:4235-4241(1990).
32. Kelleher K, Bean K, Clark SC, et al. Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in
- 15 human T-cell leukemia virus (HTLV-I-transformed human T cells. Blood 77:1436-1441(1991).
33. Houssiau FA, Schandene L, Stevens M, et al. A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10. J of Immunol. 154:2624-2630(1995).
- 20 34. Miyazawa K, Hendrie PC, Kim Y-J, et al. Recombinant human interleukin-9 induces protein tyrosine phosphorylation and synergizes with steel factor to stimulate proliferation of the human factor-dependent cell line, Mo7e. Blood 80:1685-1692(1992).
35. Yin T, Tsang M L-S, Yang Y-C. JAK1 kinase forms complexes with
- 25 interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes. J Biol Chem 269:26614-26617(1994).

- 5 36. Zav'yalov VP, Navolotskaya EV, Isaev IS, et al. Nonapeptide corresponding to the sequence 27-35 of the mature human IL-2 efficiently competes with rIL-2 for binding to thymocyte receptors. Immunol Lett 31:285-288(1992).
- 10 37. Chu JW, and Sharom FJ. Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation. Cell Immunol 145:223-239(1992).
38. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 339:324-328(1992).
- 15 39. Morely J. Cyclosporin A in asthma therapy: a pharmacological rationale. J Autoimmun 5 Suppl A:265-269(1992).
40. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, and Stone EM: The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16:325-332, 1993.
- 20 41. Orita M, Suzuki Y, Sekiya T, and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-9, 1989.
42. Sarkar G, Yoon H-S, and Sommer SS: Dideoxy fingerprint (ddF): A rapid and efficient screen for the presence of mutations. Genomics 13:441-443, 1992.
- 25 43. Cotton RG: Detection of single base changes in nucleic acids. Biochemical Journal 263(1):1-10, 1989.
44. Schwengel D, Nouri N, Meyers D, and Levitt RC: Linkage mapping of the human thromboxane A2 receptor (TBXA2R) to chromosome 19p13.3 using

- 5 transcribed 3' untranslated DNA sequence polymorphisms. Genomics
18:212-215, 1993.
45. Cytokine Handbook, Angus Thomson (1994).
46. Nicolaides, N.C. and Stoecker, C.J. A simple, efficient method for the
separate isolation of RNA and DNA from the same cells. Biotechniques
10 1996;8:154-156.
47. Ott J. Analysis of Human Genetic Linkage. Baltimore, Maryland: The
Johns Hopkins University Press, 1991.
48. Meyers DA, Postma DS, Panhuysen CIM, et al. Evidence for a locus
regulating total serum IgE levels mapping to chromosome 5. Genomics
15 1994;23:464 470.41.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Genaera Corporation
- (ii) TITLE OF INVENTION: IL-9 Receptor Variants, Useful in Treating and Diagnosing Atopic Allergies Including Asthma and Related Disorders
- (iii) NUMBER OF SEQUENCES: 36
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Deeth Williams Wall LLP
 - (B) STREET: 150 York Street, Ste. 400
 - (C) CITY: Toronto
 - (D) STATE: Ontario
 - (E) COUNTRY: Canada
 - (F) ZIP: M5H 3S5
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: CA 2,271,952
 - (B) FILING DATE: 1997-12-02
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: JP 10-525737
 - (B) FILING DATE: 1997-12-02
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/032,224
 - (B) FILING DATE: 02-DEC-1996
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/980,872
 - (B) FILING DATE: 01-DEC-1997
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: PCT/US97/21992
 - (B) FILING DATE: 02-DEC-1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME:
 - (B) REGISTRATION NUMBER:
 - (C) REFERENCE/DOCKET NUMBER:
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE:
 - (B) TELEFAX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1947 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGGCGG CCTGTGTGAA CCTGTCGTGC	60
AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGG TCTTTGCTGT	120
GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTC AGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCC CTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT	300
CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTC ACCAACAACA	360
TTCTCAGGAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCTGGC	420
TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCAGTG	480
AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGCC ATCTGACAAT TTCACCATCA	540
CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC	600
CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGGCC	660
ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACA CTTCTCAGCT	720
ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGCCCAGCAC AGGGATCACA	780
TTGTCGGGGT GACCTGGCTT AACTTTGAAG CCTTTGAGCT GGACCCTGGC TTTATCCATG	840
AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGGTAGAG GAGGAGCGTT	900
ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT CCAGGCTCCC CAGAGACAAG	960
GCCCTCTGAT CCCACCCTGG GGGTGGCCAG GCAACACCCT TGTTGCTGTG TCCATCTTTC	1020
TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGGGTG AAGAGAATCT	1080
TCTACCAGAA CGTGCCCTCT CCAGCGATGT TCTTCCAGCC CCTCTACAGT GTACACAATG	1140
GGAACTTCCA GACTTGGATG GGGGCCACCA GGGCCGGTGT GCTGTTGAGC CAGGACTGTG	1200
CTGGCACCCC ACAGGGAGCC TTGGAGCCCT GCGTCCAGGA GGCCACTGCA CTGCTCACTT	1260
GTGGCCCAGC GCGTCCTTGG AAATCTGTGG CCCTGGAGGA GGAACAGGAG GGCCCTGGGA	1320
CCAGGCTCCC GGGGAACCTG AGCTCAGAGG ATGTGCTGCC AGCAGGGTGT ACGGAGTGGA	1380

GGGTACAGAC GCTTGCCTAT CTGCCACAGG AGGACTGGGC CCCCACGTCC CTGACTAGGC	1440
CGGCTCCCCC AGACTCAGAG GGCAGCAGGA GCAGCAGCAG CAGCAGCAGC AGCAGCAACA	1500
ACAACAATA CTGTGCCTTG GGCTGCTATG GGGGATGGCA CCTCTCAGCC CTCCCAGGAA	1560
ACACACAGAG CTCTGGGCCC ATCCCAGCCC TGGCCTGTGG CCTTTCTTGT GACCATCAGG	1620
GCCTGGAGAC CCAGCAAGGA GTTGCCTGGG TGCTGGCTGG TCACTGCCAG AGGCCTGGGC	1680
TGCATGAGGA CCTCCAGGGC ATGTTGCTCC CTTCTGTCCT CAGCAAGGCT CGGTCCTGGA	1740
CATTCTAGGT CCCTGACTCG CCAGATGCAT CATGTCCATT TTGGGAAAAT GGACTGAAGT	1800
TTCTGGAGCC CTTGTCTGAG ACTGAACCTC CTGAGAAGGG GCCCCTAGCA GCGGTCAGAG	1860
GTCCTGTCTG GATGGAGGCT GGAGGCTCCC CCCTCAACCC CTCTGCTCAG TGCCTGTGGG	1920
GAGCAGCCTC TACCCTCAGC ATCCTGG	1947

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1947 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGGCGG CCTGTGTGAA CCTGTCGTGC	60
AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGG TCTTTGCTGT	120
GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTC AGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCC CTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT	300
CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTC ACCAACAACA	360
TTCTCAGGAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCTGGC	420
TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCAGTG	480
AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGCC ATCTGACAAT TTCACCATCA	540
CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC	600
CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGGCC	660
ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACA CTTCTCAGCT	720

```

ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGCCCAGCAC AGGGATCACA      780
TTGTCGGGGT GACCTGGCTT ATACTTGAAG CCTTTGAGCT GGACCCTGGC TTTATCCATG      840
AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGGTAGAG GAGGAGCGTT      900
ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT CCAGGCTCCC CAGAGACAAG      960
GCCCTCTGAT CCCACCCTGG GGGTGGCCAG GCAACACCCT TGTTGCTGTG TCCATCTTTC     1020
TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGGGTG AAGAGAATCT     1080
TCTACCAGAA CGTGCCCTCT CCAGCGATGT TCTTCCAGCC CCTCTACAGT GTACACAATG     1140
GGAACTTCCA GACTTGGATG GGGGCCCACA GGGCCGGTGT GCTGTTGAGC CAGGACTGTG     1200
CTGGCACCCC ACAGGGAGCC TTGGAGCCCT GCGTCCAGGA GGCCACTGCA CTGCTCACTT     1260
GTGGCCCAGC GCATCCTTGG AAATCTGTGG CCCTGGAGGA GGAACAGGAG GGCCCTGGGA     1320
CCAGGCTCCC GGGGAACCTG AGCTCAGAGG ATGTGCTGCC AGCAGGGTGT ACGGAGTGGA     1380
GGGTACAGAC GCTTGCCTAT CTGCCACAGG AGGACTGGGC CCCCACGTCC CTGACTAGGC     1440
CGGCTCCCCC AGACTCAGAG GGCAGCAGGA GCAGCAGCAG CAGCAGCAGC AGCAGCAACA     1500
ACAACAATA CTGTGCCTTG GGCTGCTATG GGGGATGGCA CCTCTCAGCC CTCCCAGGAA     1560
ACACACAGAG CTCTGGGCCC ATCCCAGCCC TGGCCTGTGG CCTTTCTTGT GACCATCAGG     1620
GCCTGGAGAC CCAGCAAGGA GTTGCCTGGG TGCTGGCTGG TCACTGCCAG AGGCCTGGGC     1680
TGCATGAGGA CCTCCAGGGC ATGTTGCTCC CTTCTGTCCT CAGCAAGGCT CGGTCCTGGA     1740
CATTCTAGGT CCCTGACTCG CCAGATGCAT CATGTCCATT TTGGGAAAAT GGACTGAAGT     1800
TTCTGGAGCC CTTGTCTGAG ACTGAACCTC CTGAGAAGGG GCCCCTAGCA GCGGTCAGAG     1860
GTCCTGTCTG GATGGAGGCT GGAGGCTCCC CCCTCAACCC CTCTGCTCAG TGCCTGTGGG     1920
GAGCAGCCTC TACCCTCAGC ATCCTGG                                     1947

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1944 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGGCGG CCTGTGTGAA CCTGTCGTGC      60

```

AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGG TCTTTGCTGT	120
GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTC AGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCC CTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT	300
CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTC ACCAACAACA	360
TTCTCAGGAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCTGGC	420
TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCAGTG	480
AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGCC ATCTGACAAT TTCACCATCA	540
CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC	600
CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGGCC	660
ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACA CTTCTCAGCT	720
ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGGC CCAGCACAGG GATCACATTG	780
TCGGGGTGAC CTGGCTTATA CTTGAAGCCT TTGAGCTGGA CCCTGGCTTT ATCCATGAGG	840
CCAGGCTGCG TGTCCAGATG GCCACACTGG AGGATGATGT GGTAGAGGAG GAGCGTTATA	900
CAGGCCAGTG GAGTGAGTGG AGCCAGCCTG TGTGCTTCCA GGCTCCCCAG AGACAAGGCC	960
CTCTGATCCC ACCCTGGGGG TGGCCAGGCA ACACCCTTGT TGCTGTGTCC ATCTTTCTCC	1020
TGCTGACTGG CCCGACCTAC CTCCTGTTCA AGCTGTCGCC CAGGGTGAAG AGAATCTTCT	1080
ACCAGAACGT GCCCTCTCCA GCGATGTTCT TCCAGCCCCT CTACAGTGTA CACAATGGGA	1140
ACTTCCAGAC TTGGATGGGG GCCCACAGGG CCGGTGTGCT GTTGAGCCAG GACTGTGCTG	1200
GCACCCACCA GGGAGCCTTG GAGCCCTGCG TCCAGGAGGC CACTGCACTG CTCACTTGTG	1260
GCCCAGCGCG TCCTTGGAAG TCTGTGGCCC TGGAGGAGGA ACAGGAGGGC CCTGGGACCA	1320
GGCTCCCGGG GAACCTGAGC TCAGAGGATG TGCTGCCAGC AGGGTGTACG GAGTGGAGGG	1380
TACAGACGCT TGCCTATCTG CCACAGGAGG ACTGGGCCCC CACGTCCCTG ACTAGGCCGG	1440
CTCCCCCAGA CTCAGAGGGC AGCAGGAGCA GCAGCAGCAG CAGCAGCAGC AGCAACAACA	1500
ACAACACTG TGCCTTGGGC TGCTATGGGG GATGGCACCT CTCAGCCCTC CCAGGAAACA	1560
CACAGAGCTC TGGGCCCATC CCAGCCCTGG CCTGTGGCCT TTCTTGTGAC CATCAGGGCC	1620
TGGAGACCCA GCAAGGAGTT GCCTGGGTGC TGGCTGGTCA CTGCCAGAGG CCTGGGCTGC	1680
ATGAGGACCT CCAGGGCATG TTGCTCCCTT CTGTCCTCAG CAAGGCTCGG TCCTGGACAT	1740
TCTAGGTCCC TGA CTCGCCA GATGCATCAT GTCCATTTTG GGAAAATGGA CTGAAGTTTC	1800

TGGAGCCCTT GTCTGAGACT GAACCTCCTG AGAAGGGGCC CCTAGCAGCG GTCAGAGGTC	1860
CTGTCTGGAT GGAGGCTGGA GGCTCCCCC TCAACCCCTC TGCTCAGTGC CTGTGGGGAG	1920
CAGCCTCTAC CCTCAGCATC CTGG	1944

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1862 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGGCGG CCTGTGTGAA CCTGTCGTGC	60
AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGG TCTTTGCTGT	120
GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTC AGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCC CTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT	300
CTGTCACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCTT CACCTGCCTC ACCAACAACA	360
TTCTCAGGAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCTGGC	420
TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA GTGCATCTTG CGGGGCAGTG	480
AGTGCACCGT CGTGCTGCCA CCTGAGGCAG TGCTCGTGCC ATCTGACAAT TTCACCATCA	540
CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC	600
CCCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGGCC	660
ACTGCATCCT GACCTGGAGC ATCAGTCCTG CCTTGGAGCC AATGACCACA CTTCTCAGCT	720
ATGAGCTGGC CTTCAAGAAG CAGGAAGAGG CCTGGGAGCA GGCCCAGCAC AGGGATCACA	780
TTGTCGGGGT GACCTGGCTT ATACTTGAAG CCTTTGAGCT GGACCCTGGC TTTATCCATG	840
AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGGTAGAG GAGGAGCGTT	900
ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT CCAGGCTCCC CAGAGACAAG	960
GCCCTCTGAT CCCACCCTGG GGGTGGCCAG GCAACACCCT TGTTGCTGTG TCCATCTTTC	1020
TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGACTT GGATGGGGGC	1080
CCACAGGGCC GGTGTGCTGT TGAGCCAGGA CTGTGCTGGC ACCCCACAGG GAGCCTTGGA	1140

```

GCCCTGCGTC CAGGAGGCCA CTGCACTGCT CACTTGTGGC CCAGCGCGTC CTTGGAAATC      1200
TGTGGCCCTG GAGGAGGAAC AGGAGGGCCC TGGGACCAGG CTCCCGGGGA ACCTGAGCTC      1260
AGAGGATGTG CTGCCAGCAG GGTGTACGGA GTGGAGGGTA CAGACGCTTG CCTATCTGCC      1320
ACAGGAGGAC TGGGCCCCCA CGTCCCTGAC TAGGCCGGCT CCCCAGACT CAGAGGGCAG      1380
CAGGAGCAGC AGCAGCAGCA GCAGCAGCAG CAACAACAAC AACTACTGTG CCTTGGGCTG      1440
CTATGGGGGA TGGCACCTCT CAGCCCTCCC AGGAAACACA CAGAGCTCTG GGCCCATCCC      1500
AGCCCTGGCC TGTGGCCTTT CTTGTGACCA TCAGGGCCTG GAGACCCAGC AAGGAGTTGC      1560
CTGGGTGCTG GCTGGTCACT GCCAGAGGCC TGGGCTGCAT GAGGACCTCC AGGGCATGTT      1620
GCTCCCTTCT GTCCTCAGCA AGGCTCGGTC CTGGACATTC TAGGTCCCTG ACTCGCCAGA      1680
TGCATCATGT CCATTTTGGG AAAATGGACT GAAGTTTCTG GAGCCCTTGT CTGAGACTGA      1740
ACCTCCTGAG AAGGGGCCCC TAGCAGCGGT CAGAGGTCCT GTCTGGATGG AGGCTGGAGG      1800
CTCCCCCTC AACCCTCTG CTCAGTGCCT GTGGGGAGCA GCCTCTACCC TCAGCATCCT      1860
GG                                                                 1862

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 230 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..230
- (D) OTHER INFORMATION: /note= "Base no. 1 corresponds to base no. 243 of Fig. 8. The numbering in Fig. 8 matches SEQ ID NO:1."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTC CTGGCCTGCA      60
TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTCAC AGGGGAAGGA CAAGGGCCAA      120
GGTCTAGAAC CTTACCTGC CTCACCAACA ACATTCTCAG GATCGATTGC CACTGGTCTG      180
CCCCAGAGCT GGGACAGGGC TCCAGCCCCT GGCTCCTCTT CACCAGTTAA      230

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 513 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..513
- (D) OTHER INFORMATION: /note= "Base no. 1 corresponds to base no. 208 of Fig. 6. The numbering in Fig. 6 matches SEQ ID NO:1."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTC CTGGCCTGCA      60
TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTCAC AGGGGAAGGA CAAGGGCCAA      120
GGTCTAGAAC CTTACCTGC CTCACCAACA ACATTCTCAG GATCGATTGC CACTGGTCTG      180
CCCCAGAGCT GGGACAGGGC TCCAGCCCCT GGCTCCTCTT CACCAGCAAC CAGGCTCCTG      240
GCGGCACACA TAAGTGCATC TTGCGGGGCA GTGAGTGCAC CGTCGTGCTG CCACCTGAGG      300
CAGTGCTCGT GCCATCTGAC AATTTCACCA TCACTTTCCA CCACTGCATG TCTGGGAGGG      360
AGCAGGTCAG CCTGGTGGAC CCGGAGTACC TGCCCCGGAG ACACGCTGGA CCCGCCCTCT      420
GACTTGCAGA GCAACATCAG TTCTGGCCAC TGCATCCTGA CCTGGAGCAT CAGTCCTGCC      480
TTGGAGCCAA TGACCACACT TCTCAGCTAT GAG                                     513

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 513 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..513
- (D) OTHER INFORMATION: /note= "Base no. 1 corresponds to base no. 208 of Fig. 7. The numbering in Fig. 7 matches SEQ ID NO:1."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

GCTGGACCTT GGAGAGTGAG GCCCTGAGGC GAGACATGGG CACCTGGCTC CTGGCCTGCA      60

```

TCTGCATCTG CACCTGTGTC TGCTTGGGAG TCTCTGTCAC AGGGGAAGGA CAAGGGCCAA 120
 GGTCTAGAAC CTTACCTGC CTCACCAACA ACATTCTCAG GATCGATTGC CACTGGTCTG 180
 CCCCAGAGCT GGGACAGGGC TCCAGCCCCT GGCTCCTCTT CACCAGCAAC CAGGCTCCTG 240
 GCGGCACACA TAAGTGCATC TTGCGGGGCA GTGAGTGCAC CGTCGTGCTG CCACCTGAGG 300
 CAGTGCTCGT GCCATCTGAC AATTTACCA TCACTTTCCA CCACTGCATG TCTGGGAGGG 360
 AGCAGGTCAG CCTGGTGGAC CCGGAGTACC TGCCCCGGAG ACACGAGCAA CATCAGTTCT 420
 GGCCACTGCA TCCTGACCTG GAGCATCAGT CCTGCCTTGG AGCCAATGAC CACACTTCTC 480
 AGCTATGAGC TGGCCTTCAA GAAGCAGGAA GAG 513

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCAGGTGGGG ACCCATG 17

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGGCTTGACA TCGGACAAC 19

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTGGCCTGAA GTACTTACC

19

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTGCTTCAAT CCTGGGGAA

19

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTGAGTTCCC CAGGATTGA

19

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CAAGGCCCTG CTCCAAA

17

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGGGGCTTCA GCCTCACATG

20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TATGTAGAGT GGGGAGTCTA

20

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

TGTATTCTCG AGGGCTGAG

19

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TGAGGTGAAC AGGGGAGAA

19

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CCCTGGGCCC TTCATGT

17

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ACAAGGGCGG CCTTTGAT

18

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AGGGACGAGG TGGGCGGAC

19

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCTGCCCCC ATGTTCTT

18

- 64 -

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATGCTACCTG AGCCCTTCC

19

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGACATGATG CATCTGGCG

19

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1944 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: mutation
- (B) LOCATION: 1506..1058
- (D) OTHER INFORMATION: /note= "This codon in the wild type is deleted."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGCAGCTCTG TAATGCGCTT GTGGTTTCAG ATGTGGGCGG CCTGTGTGAA CCTGTCGTGC	60
AAAGCTCACG TCACCAACTG CTGCAGTTAT CTCCTGAATC AGGCTGAGGG TCTTTGCTGT	120
GCACCCAGAG ATAGTTGGGT GACAAATCAC CTCCAGGTTG GGGATGCCTC AGACTTGTGA	180
TGGGACTGGG CAGATGCATC TGGGAAGGCT GGACCTTGGA GAGTGAGGCC CTGAGGCGAG	240
ACATGGGCAC CTGGCTCCTG GCCTGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT	300

CTGTCACAGG	GGAAGGACAA	GGGCCAAGGT	CTAGAACCTT	CACCTGCCTC	ACCAACAACA	360
TTCTCAGGAT	CGATTGCCAC	TGGTCTGCCC	CAGAGCTGGG	ACAGGGCTCC	AGCCCCTGGC	420
TCCTCTTCAC	CAGCAACCAG	GCTCCTGGCG	GCACACATAA	GTGCATCTTG	CGGGGCAGTG	480
AGTGCACCGT	CGTGCTGCCA	CCTGAGGCAG	TGCTCGTGCC	ATCTGACAAT	TTCACCATCA	540
CTTTCCACCA	CTGCATGTCT	GGGAGGGAGC	AGGTCAGCCT	GGTGGACCCG	GAGTACCTGC	600
CCCGGAGACA	CGTTAAGCTG	GACCCGCCCT	CTGACTTGCA	GAGCAACATC	AGTTCTGGCC	660
ACTGCATCCT	GACCTGGAGC	ATCAGTCCTG	CCTTGGAGCC	AATGACCACA	CTTCTCAGCT	720
ATGAGCTGGC	CTTCAAGAAG	CAGGAAGAGG	CCTGGGAGCA	GGCCCAGCAC	AGGGATCACA	780
TTGTCGGGGT	GACCTGGCTT	ATACTTGAAG	CCTTTGAGCT	GGACCCTGGC	TTTATCCATG	840
AGGCCAGGCT	GCGTGTCCAG	ATGGCCACAC	TGGAGGATGA	TGTGGTAGAG	GAGGAGCGTT	900
ATACAGGCCA	GTGGAGTGAG	TGGAGCCAGC	CTGTGTGCTT	CCAGGCTCCC	CAGAGACAAG	960
GCCCTCTGAT	CCCACCCTGG	GGGTGGCCAG	GCAACACCCT	TGTTGCTGTG	TCCATCTTTC	1020
TCCTGCTGAC	TGGCCCGACC	TACCTCCTGT	TCAAGCTGTC	GCCCAGGGTG	AAGAGAATCT	1080
TCTACCAGAA	CGTGCCCTCT	CCAGCGATGT	TCTTCCAGCC	CCTCTACAGT	GTACACAATG	1140
GGAACTTCCA	GACTTGGATG	GGGGCCCACA	GGGCCGGTGT	GCTGTTGAGC	CAGGACTGTG	1200
CTGGCACCCC	ACAGGGAGCC	TTGGAGCCCT	GCGTCCAGGA	GGCCACTGCA	CTGCTCACTT	1260
GTGGCCCAGC	GCGTCCTTGG	AAATCTGTGG	CCCTGGAGGA	GGAACAGGAG	GGCCCTGGGA	1320
CCAGGCTCCC	GGGGAACCTG	AGCTCAGAGG	ATGTGCTGCC	AGCAGGGTGT	ACGGAGTGGA	1380
GGGTACAGAC	GCTTGCCTAT	CTGCCACAGG	AGGACTGGGC	CCCCACGTCC	CTGACTAGGC	1440
CGGCTCCCCC	AGACTCAGAG	GGCAGCAGGA	GCAGCAGCAG	CAGCAGCAGC	AGCAGCAACA	1500
ACAACACTAG	TGCCTTGGGC	TGCTATGGGG	GATGGCACCT	CTCAGCCCTC	CCAGGAAACA	1560
CACAGAGCTC	TGGGCCCATC	CCAGCCCTGG	CCTGTGGCCT	TTCTTGTGAC	CATCAGGGCC	1620
TGGAGACCCA	GCAAGGAGTT	GCCTGGGTGC	TGGCTGGTCA	CTGCCAGAGG	CCTGGGCTGC	1680
ATGAGGACCT	CCAGGGCATG	TTGCTCCCTT	CTGTCCTCAG	CAAGGCTCGG	TCCTGGACAT	1740
TCTAGGTCCC	TGACTCGCCA	GATGCATCAT	GTCCATTTTG	GGAAAATGGA	CTGAAGTTTC	1800
TGGAGCCCTT	GTCTGAGACT	GAACCTCCTG	AGAAGGGGCC	CCTAGCAGCG	GTCAGAGGTC	1860
CTGTCTGGAT	GGAGGCTGGA	GGCTCCCCCC	TCAACCCCTC	TGCTCAGTGC	CTGTGGGGAG	1920
CAGCCTCTAC	CCTCAGCATC	CTGG				1944

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCTGGACCTT GGAGAGTG

18

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GTCTCAGACA AGGGCTCCAG

20

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 501 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys	1	5	10	15
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr	20	25	30	
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser	35	40	45	
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser	50	55	60	
Asn	Gln	Ala	Pro	Gly	Gly	Thr	His	Lys	Cys	Ile	Leu	Arg	Gly	Ser	Glu	65	70	75	80

- 67 -

Cys	Thr	Val	Val	Leu	Pro	Pro	Glu	Ala	Val	Leu	Val	Pro	Ser	Asp	Asn	85	90	95
Phe	Thr	Ile	Thr	Phe	His	His	Cys	Met	Ser	Gly	Arg	Glu	Gln	Val	Ser	100	105	110
Leu	Val	Asp	Pro	Glu	Tyr	Leu	Pro	Arg	Arg	His	Val	Lys	Leu	Asp	Pro	115	120	125
Pro	Ser	Asp	Leu	Gln	Ser	Asn	Ile	Ser	Ser	Gly	His	Cys	Ile	Leu	Thr	130	135	140
Trp	Ser	Ile	Ser	Pro	Ala	Leu	Glu	Pro	Met	Thr	Thr	Leu	Leu	Ser	Tyr	145	150	155
Glu	Leu	Ala	Phe	Lys	Lys	Gln	Glu	Glu	Ala	Trp	Glu	Gln	Ala	Gln	His	165	170	175
Arg	Asp	His	Ile	Val	Gly	Val	Thr	Trp	Leu	Ile	Leu	Glu	Ala	Phe	Glu	180	185	190
Leu	Asp	Pro	Gly	Phe	Ile	His	Glu	Ala	Arg	Leu	Arg	Val	Gln	Met	Ala	195	200	205
Thr	Leu	Glu	Asp	Asp	Val	Val	Glu	Glu	Glu	Arg	Tyr	Thr	Gly	Gln	Trp	210	215	220
Ser	Glu	Trp	Ser	Gln	Pro	Val	Cys	Phe	Gln	Ala	Pro	Gln	Arg	Gln	Gly	225	230	235
Pro	Leu	Ile	Pro	Pro	Trp	Gly	Trp	Pro	Gly	Asn	Thr	Leu	Val	Ala	Val	245	250	255
Ser	Ile	Phe	Leu	Leu	Leu	Thr	Gly	Pro	Thr	Tyr	Leu	Leu	Phe	Lys	Leu	260	265	270
Ser	Pro	Arg	Val	Lys	Arg	Ile	Phe	Tyr	Gln	Asn	Val	Pro	Ser	Pro	Ala	275	280	285
Met	Phe	Phe	Gln	Pro	Leu	Tyr	Ser	Val	His	Asn	Gly	Asn	Phe	Gln	Thr	290	295	300
Trp	Met	Gly	Ala	His	Arg	Ala	Gly	Val	Leu	Leu	Ser	Gln	Asp	Cys	Ala	305	310	315
Gly	Thr	Pro	Gln	Gly	Ala	Leu	Glu	Pro	Cys	Val	Gln	Glu	Ala	Thr	Ala	325	330	335
Leu	Leu	Thr	Cys	Gly	Pro	Ala	Arg	Pro	Trp	Lys	Ser	Val	Ala	Leu	Glu	340	345	350
Glu	Glu	Gln	Glu	Gly	Pro	Gly	Thr	Arg	Leu	Pro	Gly	Asn	Leu	Ser	Ser	355	360	365
Glu	Asp	Val	Leu	Pro	Ala	Gly	Cys	Thr	Glu	Trp	Arg	Val	Gln	Thr	Leu	370	375	380

- 68 -

Ala Tyr Leu Pro Gln Glu Asp Trp Ala Pro Thr Ser Leu Thr Arg Pro
 385 390 395 400
 Ala Pro Pro Asp Ser Glu Gly Ser Arg Ser Ser Ser Ser Ser Ser
 405 410 415
 Ser Ser Asn Asn Asn Asn Tyr Cys Ala Leu Gly Cys Tyr Gly Gly Trp
 420 425 430
 His Leu Ser Ala Leu Pro Gly Asn Thr Gln Ser Ser Gly Pro Ile Pro
 435 440 445
 Ala Leu Ala Cys Gly Leu Ser Cys Asp His Gln Gly Leu Glu Thr Gln
 450 455 460
 Gln Gly Val Ala Trp Val Leu Ala Gly His Cys Gln Arg Pro Gly Leu
 465 470 475 480
 His Glu Asp Leu Gln Gly Met Leu Leu Pro Ser Val Leu Ser Lys Ala
 485 490 495
 Arg Ser Trp Thr Phe
 500

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 501 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met Gly Thr Trp Leu Leu Ala Cys Ile Cys Ile Cys Thr Cys Val Cys
 1 5 10 15
 Leu Gly Val Ser Val Thr Gly Glu Gly Gln Gly Pro Arg Ser Arg Thr
 20 25 30
 Phe Thr Cys Leu Thr Asn Asn Ile Leu Arg Ile Asp Cys His Trp Ser
 35 40 45
 Ala Pro Glu Leu Gly Gln Gly Ser Ser Pro Trp Leu Leu Phe Thr Ser
 50 55 60
 Asn Gln Ala Pro Gly Gly Thr His Lys Cys Ile Leu Arg Gly Ser Glu
 65 70 75 80
 Cys Thr Val Val Leu Pro Pro Glu Ala Val Leu Val Pro Ser Asp Asn
 85 90 95
 Phe Thr Ile Thr Phe His His Cys Met Ser Gly Arg Glu Gln Val Ser

- 69 -

100						105						110					
Leu	Val	Asp	Pro	Glu	Tyr	Leu	Pro	Arg	Arg	His	Val	Lys	Leu	Asp	Pro		
		115					120					125					
Pro	Ser	Asp	Leu	Gln	Ser	Asn	Ile	Ser	Ser	Gly	His	Cys	Ile	Leu	Thr		
	130					135					140						
Trp	Ser	Ile	Ser	Pro	Ala	Leu	Glu	Pro	Met	Thr	Thr	Leu	Leu	Ser	Tyr		
145					150					155					160		
Glu	Leu	Ala	Phe	Lys	Lys	Gln	Glu	Glu	Ala	Trp	Glu	Gln	Ala	Gln	His		
				165					170					175			
Arg	Asp	His	Ile	Val	Gly	Val	Thr	Trp	Leu	Ile	Leu	Glu	Ala	Phe	Glu		
			180					185					190				
Leu	Asp	Pro	Gly	Phe	Ile	His	Glu	Ala	Arg	Leu	Arg	Val	Gln	Met	Ala		
		195					200					205					
Thr	Leu	Glu	Asp	Asp	Val	Val	Glu	Glu	Glu	Arg	Tyr	Thr	Gly	Gln	Trp		
	210						215				220						
Ser	Glu	Trp	Ser	Gln	Pro	Val	Cys	Phe	Gln	Ala	Pro	Gln	Arg	Gln	Gly		
225					230					235					240		
Pro	Leu	Ile	Pro	Pro	Trp	Gly	Trp	Pro	Gly	Asn	Thr	Leu	Val	Ala	Val		
				245					250					255			
Ser	Ile	Phe	Leu	Leu	Leu	Thr	Gly	Pro	Thr	Tyr	Leu	Leu	Phe	Lys	Leu		
			260					265					270				
Ser	Pro	Arg	Val	Lys	Arg	Ile	Phe	Tyr	Gln	Asn	Val	Pro	Ser	Pro	Ala		
		275					280					285					
Met	Phe	Phe	Gln	Pro	Leu	Tyr	Ser	Val	His	Asn	Gly	Asn	Phe	Gln	Thr		
	290					295					300						
Trp	Met	Gly	Ala	His	Arg	Ala	Gly	Val	Leu	Leu	Ser	Gln	Asp	Cys	Ala		
305					310					315					320		
Gly	Thr	Pro	Gln	Gly	Ala	Leu	Glu	Pro	Cys	Val	Gln	Glu	Ala	Thr	Ala		
				325					330					335			
Leu	Leu	Thr	Cys	Gly	Pro	Ala	His	Pro	Trp	Lys	Ser	Val	Ala	Leu	Glu		
			340					345					350				
Glu	Glu	Gln	Glu	Gly	Pro	Gly	Thr	Arg	Leu	Pro	Gly	Asn	Leu	Ser	Ser		
		355					360					365					
Glu	Asp	Val	Leu	Pro	Ala	Gly	Cys	Thr	Glu	Trp	Arg	Val	Gln	Thr	Leu		
	370					375					380						
Ala	Tyr	Leu	Pro	Gln	Glu	Asp	Trp	Ala	Pro	Thr	Ser	Leu	Thr	Arg	Pro		
385					390					395					400		
Ala	Pro	Pro	Asp	Ser	Glu	Gly	Ser	Arg	Ser	Ser	Ser	Ser	Ser	Ser	Ser		

- 70 -

				405					410					415		
Ser	Ser	Asn	Asn	Asn	Asn	Tyr	Cys	Ala	Leu	Gly	Cys	Tyr	Gly	Gly	Trp	
			420					425					430			
His	Leu	Ser	Ala	Leu	Pro	Gly	Asn	Thr	Gln	Ser	Ser	Gly	Pro	Ile	Pro	
		435					440					445				
Ala	Leu	Ala	Cys	Gly	Leu	Ser	Cys	Asp	His	Gln	Gly	Leu	Glu	Thr	Gln	
	450					455					460					
Gln	Gly	Val	Ala	Trp	Val	Leu	Ala	Gly	His	Cys	Gln	Arg	Pro	Gly	Leu	
465					470					475					480	
His	Glu	Asp	Leu	Gln	Gly	Met	Leu	Leu	Pro	Ser	Val	Leu	Ser	Lys	Ala	
				485					490					495		
Arg	Ser	Trp	Thr	Phe												
				500												

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys
1				5					10					15	
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr
			20					25					30		
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser
		35					40					45			
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser
	50					55					60				
Asn	Gln	Ala	Pro	Gly	Gly	Thr	His	Lys	Cys	Ile	Leu	Arg	Gly	Ser	Glu
65				70						75					80
Cys	Thr	Val	Val	Leu	Pro	Pro	Glu	Ala	Val	Leu	Val	Pro	Ser	Asp	Asn
				85					90					95	
Phe	Thr	Ile	Thr	Phe	His	His	Cys	Met	Ser	Gly	Arg	Glu	Gln	Val	Ser
			100					105					110		
Leu	Val	Asp	Pro	Glu	Tyr	Leu	Pro	Arg	Arg	His	Val	Lys	Leu	Asp	Pro
		115					120					125			

- 71 -

Pro	Ser	Asp	Leu	Gln	Ser	Asn	Ile	Ser	Ser	Gly	His	Cys	Ile	Leu	Thr	130	135	140
Trp	Ser	Ile	Ser	Pro	Ala	Leu	Glu	Pro	Met	Thr	Thr	Leu	Leu	Ser	Tyr	145	150	155
Glu	Leu	Ala	Phe	Lys	Lys	Gln	Glu	Glu	Ala	Trp	Glu	Ala	Gln	His	Arg	165	170	175
Asp	His	Ile	Val	Gly	Val	Thr	Trp	Leu	Ile	Leu	Glu	Ala	Phe	Glu	Leu	180	185	190
Asp	Pro	Gly	Phe	Ile	His	Glu	Ala	Arg	Leu	Arg	Val	Gln	Met	Ala	Thr	195	200	205
Leu	Glu	Asp	Asp	Val	Val	Glu	Glu	Glu	Arg	Tyr	Thr	Gly	Gln	Trp	Ser	210	215	220
Glu	Trp	Ser	Gln	Pro	Val	Cys	Phe	Gln	Ala	Pro	Gln	Arg	Gln	Gly	Pro	225	230	235
Leu	Ile	Pro	Pro	Trp	Gly	Trp	Pro	Gly	Asn	Thr	Leu	Val	Ala	Val	Ser	245	250	255
Ile	Phe	Leu	Leu	Leu	Thr	Gly	Pro	Thr	Tyr	Leu	Leu	Phe	Lys	Leu	Ser	260	265	270
Pro	Arg	Val	Lys	Arg	Ile	Phe	Tyr	Gln	Asn	Val	Pro	Ser	Pro	Ala	Met	275	280	285
Phe	Phe	Gln	Pro	Leu	Tyr	Ser	Val	His	Asn	Gly	Asn	Phe	Gln	Thr	Trp	290	295	300
Met	Gly	Ala	His	Arg	Ala	Gly	Val	Leu	Leu	Ser	Gln	Asp	Cys	Ala	Gly	305	310	315
Thr	Pro	Gln	Gly	Ala	Leu	Glu	Pro	Cys	Val	Gln	Glu	Ala	Thr	Ala	Leu	325	330	335
Leu	Thr	Cys	Gly	Pro	Ala	Arg	Pro	Trp	Lys	Ser	Val	Ala	Leu	Glu	Glu	340	345	350
Glu	Gln	Glu	Gly	Pro	Gly	Thr	Arg	Leu	Pro	Gly	Asn	Leu	Ser	Ser	Glu	355	360	365
Asp	Val	Leu	Pro	Ala	Gly	Cys	Thr	Glu	Trp	Arg	Val	Gln	Thr	Leu	Ala	370	375	380
Tyr	Leu	Pro	Gln	Glu	Asp	Trp	Ala	Pro	Thr	Ser	Leu	Thr	Arg	Pro	Ala	385	390	395
Pro	Pro	Asp	Ser	Glu	Gly	Ser	Arg	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	405	410	415
Ser	Asn	Asn	Asn	Asn	Tyr	Cys	Ala	Leu	Gly	Cys	Tyr	Gly	Gly	Trp	His	420	425	430

[illegible]

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 286 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Met 1	Gly	Thr	Trp	Leu 5	Leu	Ala	Cys	Ile	Cys 10	Ile	Cys	Thr	Cys	Val 15	Cys
Leu	Gly	Val	Ser 20	Val	Thr	Gly	Glu	Gly 25	Gln	Gly	Pro	Arg	Ser 30	Arg	Thr
Phe	Thr	Cys 35	Leu	Thr	Asn	Asn	Ile 40	Leu	Arg	Ile	Asp 45	Cys	His	Trp	Ser
Ala	Pro 50	Glu	Leu	Gly	Gln	Gly 55	Ser	Ser	Pro	Trp	Leu 60	Leu	Phe	Thr	Ser
Asn 65	Gln	Ala	Pro	Gly	Gly 70	Thr	His	Lys	Cys	Ile 75	Leu	Arg	Gly	Ser	Glu 80
Cys	Thr	Val	Val	Leu 85	Pro	Pro	Glu	Ala	Val 90	Leu	Val	Pro	Ser	Asp 95	Asn
Phe	Thr	Ile	Thr 100	Phe	His	His	Cys	Met 105	Ser	Gly	Arg	Glu	Gln 110	Val	Ser
Leu	Val	Asp 115	Pro	Glu	Tyr	Leu	Pro 120	Arg	Arg	His	Val	Lys 125	Leu	Asp	Pro
Pro	Ser 130	Asp	Leu	Gln	Ser	Asn 135	Ile	Ser	Ser	Gly	His 140	Cys	Ile	Leu	Thr
Trp 145	Ser	Ile	Ser	Pro	Ala 150	Leu	Glu	Pro	Met	Thr 155	Thr	Leu	Leu	Ser	Tyr 160

- 73 -

Glu	Leu	Ala	Phe	Lys	Lys	Gln	Glu	Glu	Ala	Trp	Glu	Gln	Ala	Gln	His
				165					170					175	
Arg	Asp	His	Ile	Val	Gly	Val	Thr	Trp	Leu	Ile	Leu	Glu	Ala	Phe	Glu
			180					185					190		
Leu	Asp	Pro	Gly	Phe	Ile	His	Glu	Ala	Arg	Leu	Arg	Val	Gln	Met	Ala
		195					200					205			
Thr	Leu	Glu	Asp	Asp	Val	Val	Glu	Glu	Glu	Arg	Tyr	Thr	Gly	Gln	Trp
	210					215					220				
Ser	Glu	Trp	Ser	Gln	Pro	Val	Cys	Phe	Gln	Ala	Pro	Gln	Arg	Gln	Gly
225					230					235					240
Pro	Leu	Ile	Pro	Pro	Trp	Gly	Trp	Pro	Gly	Asn	Thr	Leu	Val	Ala	Val
				245					250					255	
Ser	Ile	Phe	Leu	Leu	Leu	Thr	Gly	Pro	Thr	Tyr	Leu	Leu	Phe	Lys	Leu
			260					265					270		
Ser	Pro	Arg	Leu	Gly	Trp	Gly	Pro	Thr	Gly	Pro	Val	Cys	Cys		
		275					280					285			

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 64 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys
1				5					10					15	
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr
			20					25					30		
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser
		35					40					45			
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser
	50					55					60				

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 128 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

- 74 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys	1	5	10	15
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr	20	25	30	
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser	35	40	45	
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser	50	55	60	
Asn	Gln	Ala	Pro	Gly	Gly	Thr	His	Lys	Cys	Ile	Leu	Arg	Gly	Ser	Glu	65	70	75	80
Cys	Thr	Val	Val	Leu	Pro	Pro	Glu	Ala	Val	Leu	Val	Pro	Ser	Asp	Asn	85	90	95	
Phe	Thr	Ile	Thr	Phe	His	His	Cys	Met	Ser	Gly	Arg	Glu	Gln	Val	Ser	100	105	110	
Leu	Val	Asp	Pro	Glu	Tyr	Leu	Pro	Arg	Arg	His	Ala	Gly	Pro	Ala	Leu	115	120	125	

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys	1	5	10	15
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr	20	25	30	
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser	35	40	45	
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser	50	55	60	
Asn	Gln	Ala	Pro	Gly	Gly	Thr	His	Lys	Cys	Ile	Leu	Arg	Gly	Ser	Glu	65	70	75	80

Met	Gly	Thr	Trp	Leu	Leu	Ala	Cys	Ile	Cys	Ile	Cys	Thr	Cys	Val	Cys
1				5					10					15	
Leu	Gly	Val	Ser	Val	Thr	Gly	Glu	Gly	Gln	Gly	Pro	Arg	Ser	Arg	Thr
			20					25					30		
Phe	Thr	Cys	Leu	Thr	Asn	Asn	Ile	Leu	Arg	Ile	Asp	Cys	His	Trp	Ser
		35					40					45			
Ala	Pro	Glu	Leu	Gly	Gln	Gly	Ser	Ser	Pro	Trp	Leu	Leu	Phe	Thr	Ser
	50					55					60				
Asn	Gln	Ala	Pro	Gly	Gly	Thr	His	Lys	Cys	Ile	Leu	Arg	Gly	Ser	Glu
65				70						75					80
Cys	Thr	Val	Val	Leu	Pro	Pro	Glu	Ala	Val	Leu	Val	Pro	Ser	Asp	Asn
				85					90					95	
Phe	Thr	Ile	Thr	Phe	His	His	Cys	Met	Ser	Gly	Arg	Glu	Gln	Val	Ser
			100					105					110		
Leu	Val	Asp	Pro	Glu	Tyr	Leu	Pro	Arg	Arg	His	Val	Lys	Leu	Asp	Pro
		115					120					125			

Pro	Ser	Asp	Leu	Gln	Ser	Asn	Ile	Ser	Ser	Gly	His	Cys	Ile	Leu	Thr	
	130					135					140					
Trp	Ser	Ile	Ser	Pro	Ala	Leu	Glu	Pro	Met	Thr	Thr	Leu	Leu	Ser	Tyr	
145					150					155					160	
Glu	Leu	Ala	Phe	Lys	Lys	Gln	Glu	Glu	Ala	Trp	Glu	Gln	Ala	Gln	His	
				165					170					175		
Arg	Asp	His	Ile	Val	Gly	Val	Thr	Trp	Leu	Ile	Leu	Glu	Ala	Phe	Glu	
			180					185					190			
Leu	Asp	Pro	Gly	Phe	Ile	His	Glu	Ala	Arg	Leu	Arg	Val	Gln	Met	Ala	
		195					200					205				
Thr	Leu	Glu	Asp	Asp	Val	Val	Glu	Glu	Glu	Arg	Tyr	Thr	Gly	Gln	Trp	
	210					215					220					
Ser	Glu	Trp	Ser	Gln	Pro	Val	Cys	Phe	Gln	Ala	Pro	Gln	Arg	Gln	Gly	
225					230					235					240	
Pro	Leu	Ile	Pro	Pro	Trp	Gly	Trp	Pro	Gly	Asn	Thr	Leu	Val	Ala	Val	
				245					250					255		
Ser	Ile	Phe	Leu	Leu	Leu	Thr	Gly	Pro	Thr	Tyr	Leu	Leu	Phe	Lys	Leu	
			260					265					270			
Ser	Pro	Arg	Val	Lys	Arg	Ile	Phe	Tyr	Gln	Asn	Val	Pro	Ser	Pro	Ala	
		275					280					285				
Met	Phe	Phe	Gln	Pro	Leu	Tyr	Ser	Val	His	Asn	Gly	Asn	Phe	Gln	Thr	
	290					295					300					
Trp	Met	Gly	Ala	His	Arg	Ala	Gly	Val	Leu	Leu	Ser	Gln	Asp	Cys	Ala	
305					310					315					320	
Gly	Thr	Pro	Gln	Gly	Ala	Leu	Glu	Pro	Cys	Val	Gln	Glu	Ala	Thr	Ala	
				325					330					335		
Leu	Leu	Thr	Cys	Gly	Pro	Ala	Arg	Pro	Trp	Lys	Ser	Val	Ala	Leu	Glu	
			340					345					350			
Glu	Glu	Gln	Glu	Gly	Pro	Gly	Thr	Arg	Leu	Pro	Gly	Asn	Leu	Ser	Ser	
		355					360					365				
Glu	Asp	Val	Leu	Pro	Ala	Gly	Cys	Thr	Glu	Trp	Arg	Val	Gln	Thr	Leu	
	370					375					380					
Ala	Tyr	Leu	Pro	Gln	Glu	Asp	Trp	Ala	Pro	Thr	Ser	Leu	Thr	Arg	Pro	
385					390					395					400	
Ala	Pro	Pro	Asp	Ser	Glu	Gly	Ser	Arg	Ser	Ser	Ser	Ser	Ser	Ser	Ser	
				405					410					415		
Ser	Ser	Asn	Asn	Asn	Tyr	Cys	Ala	Leu	Gly	Cys	Tyr	Gly	Gly	Trp	His	
			420					425					430			

```
(ix) FEATURE:
      (A) NAME/KEY: misc_feature
      (B) LOCATION: 1..70
      (D) OTHER INFORMATION: /note= "Base no. 1 corresponds to base
          no. 81 of intron 5."
```

(ix) FEATURE:

(A) NAME/KEY: mutation

(B) LOCATION: 133

(D) OTHER INFORMATION: /note= "T to C substitution in intron
5."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

AAGTGTGATG AGTGTGAAAG TGTTCTGTGA GACATGTTTG CCTGTGTGTG CACATGTGTA 60

TTTGTGGGCA 70

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a human interleukin-9 receptor variant comprising one or more variations in the nucleic acid sequence selected from the group consisting of a G to A substitution corresponding to position 1273 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 759 to 761 of SEQ ID NO: 1, a stop codon at nucleotides corresponding to positions 435 to 437 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 613 to 617 of SEQ ID NO: 1, deletion of nucleotides corresponding to positions 613 to 641 of SEQ ID NO: 1; deletion of nucleotides corresponding to positions 1067 to 1151 of SEQ ID NO: 1, wherein the isolated nucleic acid molecule encodes a protein that binds to IL-9.
2. The isolated nucleic acid molecule of claim 1 wherein the human interleukin-9 receptor variant with G to A substitution corresponding to position 1273 of SEQ ID NO: 1 comprises the nucleotide sequence of SEQ ID NO: 2.
3. The isolated nucleic acid molecule of claim 1 wherein the human interleukin-9 receptor variant with deletion of nucleotides corresponding to positions 759 to 761 of SEQ ID NO: 1 comprises the nucleotide sequence of SEQ ID NO: 3.
4. The isolated nucleic acid molecule of claim 1 wherein the human interleukin-9 receptor variant with a stop codon at nucleotides corresponding to positions 435 to 437 of SEQ ID NO: 1 comprises the nucleotide sequence of SEQ ID NO: 5.
5. The isolated nucleic acid molecule of claim 1 wherein the human interleukin-9 receptor variant with a deletion of nucleotides corresponding to positions 613 to 617 of SEQ ID NO: 1 comprises the nucleotide sequence of SEQ ID NO: 6.
6. The isolated nucleic acid molecule of claim 1 wherein the human interleukin-9 receptor variant with a deletion of nucleotides corresponding to positions 613 to 641 of SEQ ID NO: 1 comprises the nucleotide sequence of SEQ ID NO: 7.
7. The isolated nucleic acid molecule of claim 1 wherein the human interleukin-9 receptor variant with a deletion of nucleotides corresponding to positions 1067 to 1151 of SEQ ID NO: 1 comprises the nucleotide sequence of SEQ ID NO: 4.

8. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:36, wherein the nucleotide sequence contains the fifth intron of human IL-9 receptor in which the nucleotide corresponding to position 133 of intron five has been changed from T to C, and wherein the isolated nucleic acid molecule encodes a protein that binds to IL-9.

9. The isolated nucleic acid molecule according to any one of claims 1 to 8 wherein the nucleic acid is DNA.

10. The isolated nucleic acid molecule according to any one of claims 1 to 8 wherein the nucleic acid is RNA.

11. An isolated human interleukin-9 receptor variant protein comprising an amino acid sequence containing one or more variations selected from the group consisting of a sequence containing a histidine at position 344 corresponding to SEQ ID NO: 27, a sequence wherein glutamine corresponding to amino acid 173 of SEQ ID NO: 27 has been deleted, a sequence wherein the molecule is terminated after amino acid 64 corresponding to SEQ ID NO: 27, a sequence wherein the molecule is encoded by the nucleic acid molecule of any one of claims 5, 6, 7, and a sequence containing one or more of the variations which binds to IL-9.

12. The isolated human interleukin-9 receptor variant protein molecule of claim 11 wherein the variant with a histidine at position 344 corresponding to SEQ ID NO: 27 comprises the amino acid sequence of SEQ ID NO: 28.

13. The isolated human interleukin-9 receptor variant protein molecule of claim 11 wherein the deletion of glutamine corresponding to amino acid 173 of SEQ ID NO: 27 comprises the amino acid sequence of SEQ ID NO: 29.

14. The isolated human interleukin-9 receptor variant protein molecule of claim 11 wherein the variant encoded by the nucleic acid molecule of claim 7 comprises the amino acid sequence of SEQ ID NO: 30.

15. The isolated human interleukin-9 receptor variant protein molecule of claim 11 wherein the variant with a termination after amino acid 64 corresponding to SEQ ID NO: 27 comprises the amino acid sequence of SEQ ID NO: 31.

16. The isolated human interleukin-9 receptor variant protein molecule of claim 11 wherein the molecule encoded by the nucleic acid molecule of claim 5 comprises the amino acid sequence of SEQ ID NO: 32.

17. The isolated human interleukin-9 receptor variant protein molecule of claim 11 wherein the molecule encoded by the nucleic acid molecule of claim 6 comprises the amino acid sequence of SEQ ID NO: 33.

18. A method for detecting or diagnosing susceptibility to asthma or a related disorder in a human subject comprising determining the presence or absence of the nucleic acid molecule of any one of claims 2 to 7 wherein the presence of only said nucleic acid molecule indicates greater susceptibility to asthma or inflammatory disorders with reversible airflow obstruction.

19. A method for detecting or diagnosing susceptibility to asthma or a related disorder in a human subject comprising determining the presence or absence of the nucleic acid molecule of claim 8 wherein the presence of only said nucleic acid molecule indicates greater susceptibility to asthma or inflammatory disorders with reversible airflow obstruction.

20. An isolated nucleic acid molecule encoding any one of the proteins of claims 12 to 17.

21. Use of an effective amount of the protein of any one of claims 11 to 17 for the preparation of a medicament for the alleviation of asthma and inflammatory disorders with reversible airflow obstruction.

HUMAN IL-9 RECEPTOR cDNA




FIG. 1

250 * * * * * 260 270 280 290 300 310 320 330 340 350 360 370 380
 ATGGGCAC CTGGCTCCTG GCGTCGCACT GCATCTGCAC CTGTGCTCTGC TTGGGAGTCT CTGTACACAG GGAAGGACAA GGGCCAAGGT CTAGAACCCT CACCTGCCCTC ACCACACACA TTCTCAGGAT CGATTGGCCAC
 M G T W L L A C I C I C T C V C L G V S V T G E G Q G P R S R T F T C L T N N I L R I D C H>
 390 * * * * * 400 410 420 430 440 450 460 470 480 490 500 510 520
 TGGTCTGCCC CAGAGCTGG ACAGGGCTCC AGCCCTTGGC TCCTCTTAC CAGCAACCAG GCTCTTGGCG GCACACATAA GTGCATCTTG CGGGCAGTG AGTGACCCGT CGTGCCTGCCA CCTGAGGCAG TGCTCTGGCC
 W S A P E L G Q G S S P W L L F T S N Q A P G G T H K C I L R G S E C T V V L P P E A V L V P>
 530 * * * * * 540 550 560 570 580 590 600 610 620 630 640 650 660
 ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCATGTCT GGTAGGAGC AGGTCAGCCT GGTGGACCCG GAGTACCTGC CCGGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCTGGCC
 S D N F T I T F H H C M S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>
 670 * * * * * 680 690 700 710 720 730 740 750 760 770 780 790 800
 ACTGCATCCT GACCTGGAGC ATCAGTCTTG CCTTGGAGCC AATGACCACA CTTCTCAGCT ATGAGCTGGC CAGGAAGAGG CCTGGGAGCA GGGCCAGCAC AGGGATCACA TTGTCCGGGT GACCTGGCTT
 H C I L T W S I S P A L E P M T T L L S Y E L A F K K Q E E A W E Q A Q H R D H I V G V T W L>
 810 * * * * * 820 830 840 850 860 870 880 890 900 910 920 930 940
 ATACTTGAAG CCTTTGAGCT GGACCCCTGG TTTATTCATG AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATCA TGTTGGTAGAG GAGGAGCGTT ATACAGGCA GTGGAGTGAG TGGAGCCAGC CTGTGTGCTT
 I L E A F E L D P G F I H E A R L R V Q M A T L E D D V V E E E R Y T G Q W S E W S Q P V C F>
 950 * * * * * 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
 CCAGGCTCCC CAGAGACAAG GCGCTCTGAT CCCACCTTGG GGTGGCCAG GCAACACCCCT TGTTCCTTG TCCATCTTTC TCGCTCTGAC TGGCCCGACC TACCTCTGTT TCAAGCTGTC GCCCAGGGTG AAGAGATCT
 Q A P Q R Q G P L I P P W G W P G N T L V A V S I F L L L T G P T Y L L F K L S P R V K R I>

FIG. 2-1

1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
TTTACCAGAA	CGTGGCCCTCT	CCAGCGATGT	TCTTCCAGCC	CCTCTACAGT	GTACACAATG	GGAATCTTCA	GACTTGGATG	GGGGCCGATG	GGGCGGTGT	GCTGTTCAGC	CAGGACTGTG	CTGGCACCCC	ACAGGGAGCC
F Y Q N	V P S P A M	F F Q P L Y S	V H N G N F Q	T W M G A H	R A G V L L S	Q D C A G	T P Q G A>	1230	1240	1250	1260	1270	1280
1230	1240	1250	1260	1270	1280	1290	1300	1310	1320	1330	1340	1350	1360
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
TTTGAGCCCT	GCGTCCAGGA	GGCCACTGCA	CTGCTCACTT	GTGGCCACGC	GGTCCCTTGG	AAATCTGTGG	CCCTGGAGGA	GGAACAGGAG	GGCCCTTGGG	CCAGGCTCCC	GGGGAACCTG	AGCTCAGAGG	ATGTGCTGCC
L E P C	V Q E A T A	L L T C G P A	R P W K S V	A L E E Q E	G P G T R L P	G N L S S E	D V L P>	1370	1380	1390	1400	1410	1420
1370	1380	1390	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	1500
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
AGCAGGCTGT	ACGGAGTGGG	GGGTACAGAC	GCTTGCCTAT	CTGCCACAGG	AGGACTGGGC	CCCCACGTCC	CTGACTAGGC	CGGCTCCCCC	AGACTCAGAG	GGCAGCAGGA	GCAGCAGCAG	CAGCAGCAGC	AGCAACAACA
A G C T	E W R V Q T	L A Y L P Q	E D W A P T	S L T R P A	P P D S E G	S R S S S S	S S N N>	1510	1520	1530	1540	1550	1560
1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
ACAACACTAG	TGCCTTGGGC	TGCTATGGGG	GATGGACCTT	CTCAGCCCTC	CACAGAGCTC	TGGGCCCATC	CCAGCCCTGG	CCCTGTGGCT	TCTTGTGAC	CATCAGGGCC	TGGAGACCCA	GCAAGGAGTT	
N N Y C	A L G C Y G	G W H L S A	L P G N T Q	S S G P I P	A L A C G L	S C D H Q	G L E T Q	Q G V>	1650	1660	1670	1680	1690
1650	1660	1670	1680	1690	1700	1710	1720	1730	1740	1750	1760	1770	1780
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
GCTTGGGTGC	TGGCTGTGCA	CTGCCAGAGG	CCTGGGCTGC	ATGAGGACCT	CCAGGGCATG	TTCCTCCCTT	CTGTCTCTCAG	CAAGGCTGG	TCCGTGGACAT	TCTAGGTCCC	TGACTCGCCA	GATGCATCAT	GTCCATTTTG
A W V L	A G H C Q R	P G L H E D	L Q G M L L P	S V L S K A	R S W T F * V	P D S P D A	S C P F W>	1790	1800	1810	1820	1830	1840
1790	1800	1810	1820	1830	1840	1850	1860	1870	1880	1890	1900	1910	1920
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
GGAAATGGA	CTGAAGTTTC	TGGAGCCCTT	GTCTGAGACT	GAACTCTCTG	AGAAGGGGCC	CCTAGCAGCG	CTCAGAGGTC	CTGTCTGGAT	GGAGGCTGGA	GGCTCCCCC	TCAACCCCTC	TGCTCAGTGC	CTGTGGGGAG
E N G L	K F L E P L	S E T E P P	E K G P L A	A V R G P V	W M E A G G	S P L N P S	A Q C L W G>	1930	1940				
1930	1940												
* * *	* * *												
CAGCCCTTAC	CCTCAGCATC	CTGG											
A A S T	L S I L>												

3 / 24

FIG. 2-2

[illegible]

SUBSTITUTE SHEET (RULE 26)

FIG. 3-1

[illegible]

FIG. 3-2

250 260 270 280 290 300 310 320 330 340 350 360 370 380

* *

ATGGGCAC CTGGCTCCTG GCGTGCATCT GCACTTGCAC CTGTGTCCTGCT TTTGGGAGTCT CTGTACACAGG GGAAGGACAA GGGCCAAGGT CTAGAACCCT CACCTGCCCTC ACCAACACAA TTCTCAGGAT CGATTGCCAC

M G T W L L A C I C I C T C V C L G V S V T G E G Q G P R S R T F T C L T N N I L R I D C H>

390 400 410 420 430 440 450 460 470 480 490 500 510 520

* *

TGGTCTGCCC CAGAGCTGG ACAGGGCTCC AGCCCTGACC TCCTCTTCAC CAGCAACCAG GCTCTCTGGG GCACACATAA GTGCATCTTG CCGGGCAGTG AGTGCACCGT CGTCTCTGCCA CCTGAGGCAG TGCTCTGTGCC

W S A P E L G Q G S S P W L L F T S N Q A P G G T H K C I L R G S E C T V V L P P E A V L V P>

530 540 550 560 570 580 590 600 610 620 630 640 650 660

* *

ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCATGTCT GGGAGGGAGC AGGTCAGCCT GGTGGACCG GAGTACCTGC CCGGAGACA CGTTAAGCTG GACCCGCCCT CTGACTTGCA GAGCAACATC AGTTCGTGCC

S D N F T I T F H H C M S G R E Q V S L V D P E Y L P R R H V K L D P P S D L Q S N I S S G>

670 680 690 700 710 720 730 740 750 760 770 780 790 800

* *

ACTGCATCCT GACCTGGAGC ATCAGTCTTG CTTTGGAGCC AATGACCACA CTTCTCAGCT ATGAGCTGGC CTTCAAGAG CAGGAAGAGG CCGGGAGCA GGGCCAGCAC AGGGATCACA TTGTGGGGT GACCTGGCTT

H C I L T W S I S P A L E P M T T L L S Y E L A F K K Q E E A W E Q A Q H R D H I V G V T W L>

810 820 830 840 850 860 870 880 890 900 910 920 930 940

* *

ATACTTGAAG CCTTTGAGCT GGACCCCTGGC TTTATCCATG AGGCCAGGCT GCGTGTCCAG ATGGCCACAC TGGAGGATGA TGTGTAGAG GAGGAGCGTT ATACAGGCCA GTGGAGTGAG TGGAGCCAGC CTGTCTGTCTT

I L E A F E L D P G F I H E A R L R V Q M A T L E D D V V E E R Y T G Q W S E W S Q P V C F>

950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080

* *

CCAGGCTCCC CAGAGACAAG GCGCTCTGAT CCCACCTTGG GGGTGGCCAG GCAACACCCCT TGTGTCTGTG TCCATCTTTC TCCTGCTGAC TGGCCCGACC TACCTCCTGT TCAAGCTGTC GCCCAGACTT GGATGGGGGC

Q A P Q R Q G P L I P P W G W P G N T L V A V S I F L L L T G P T Y L L F K L S P R L G W G>

1090 1100

* * * * *

CCACAGGGCC GGTGTGTGT TGA

P T G P V C C *>

FIG. 4

[illegible]

7 / 24

FIG. 5-1

SUBSTITUTE SHEET (RULE 26)

FIG. 5-2

210 220 230 240 250 260 270 280 290 300 310 320 330
GCT GGACCTTGGG GAGTGGAGCC CTGAGGGGAG ACAATGGGCAC CTGGCTCCCTG GCCTGGCATCT GCATCTGCAC CTGTGTCTGC TTGGGAGTCT CTGTTCACAGG GGAAGGACAA GGGCCCAAGGT
340 350 360 370 380 390 400 410 420 430 440 450 460
M G T W L L A C I C T C V C L G V S V T G E G Q G P R>
CTAGAACCTT CACCTGCCTC ACCAACAACA TTCTCAGGAT CGATTGGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCTTGGC TCCTCTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA
S R T F T C L T N N I L R I D C H W S A P E L G Q G S S P W L L F T S N Q A P G G T H K>
470 480 490 500 510 520 530 540 550 560 570 580 590
GTGCATCTTG CGGGGCAGTG AGTGACCCGT CGTGTGCCCC ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCAATGCT GGGAGGGAGC AGTTCAGCCT GGTGGACCCG
C I L R G S E C T V V L P P E A V L V P S D N F T I T F H H C M S G R E Q V S L V D P>
600 610 620 630 640 650 660 670 680 690 700 710 720
GAGTACCTGC CCGGGAGACA CGCTGGACCC GCGCTCTGAC ACATCAGTTC TGGCCACTGC ATCTGACCT GGAGCATCAG TCCTGCCCTTG GAGCCATGA CCACACTTCT CAGCTATGAG
E Y L P R R H A G P A L>

FIG. 6

210 220 230 240 250 260 270 280 290 300 310 320 330
GCT GGACCTTGGG GAGTGAGGCC CTGAGGCGAG ACAATGGGCAC CTGGCTCCTG GCCTGCACTT GCATCTGCAC CTGTGCTGCG TTGGGAGTCT CTGTACACAG GGAAGGACAA GGCCCAAGGT
M G T W L L A C I C I C T C V C L G V S V T G E G Q G P R>
340 350 360 370 380 390 400 410 420 430 440 450 460
CTAGAACCCT CACCTGCCCT ACCAACAACA TTCTCAGCAT CGATTGCCAC TGGTCTGCCC CAGAGCTGGG ACAGGGCTCC AGCCCCCTGG TCCTCTTTCAC CAGCAACCAG GCTCCTGGCG GCACACATAA
S R T F T C L T N N I L R I D C H W S A P E L G Q G S S P W L L F T S N Q A P G G T H K>
470 480 490 500 510 520 530 540 550 560 570 580 590
GTGCACTTGG CGGGGAGTG AGTGCACCGT CGTGTGCGCA CCTGAGGCAG TGCTGCTGCC ATCTGACAAT TTCACCATCA CTTTCCACCA CTGCATGCTT GGGAGGGAGC AGGTCAAGCT GGTGGACCCG
C I L R G S E C T V V L P P E A V L V P S D N F T I T F H H C M S G R E Q V S L V D P>
600 610 620 630 640 650 660 670 680 690 700 710 720
GAGTACCTGC CCGGAGACA CGAGCAACAT CAGTTCTGGC CACTGCATCC TGACCTGGAG CATCAGTCTT GCCTTGGAGC CAATGACCAC ACTTCTCAGC TATGAGCTGG CCTTCAAGAA GCAGGAAGAG
E Y L P R R H E Q H Q F W P L H P D L E H Q S C L G A N D H T S Q L>

FIG. 7

SEQUENCE RANGE: 243 TO 437

250	260	270	280	290	300	310	320	330	340	350	360	370	380
* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *	* * *
ATGGGCAC	CTGGCTCCG	GCGTGCATCT	GCATCTGCAC	CTGTCTCTGC	TTGGGAGTCT	CTGTCAcAGG	GGAGGACAA	GGCCCAAGGT	CTAGAACCCT	CACCTGCCCTC	ACCAACAACA	TTCTCAGGAT	CGATTGCCAC
M G T	W L L	A C I	C T C	V C L	G V S	V T G	E G Q	G P R	S R T	F T C	L T N	N I L	R I D
390	400	410	420	430									
* * *	* * *	* * *	* * *	* * *	* * *								
TTGGTCTGCC	CAGAGCTGG	ACAGGGCTCC	AGCCCCTGGC	TCCTCTTCAC	CAGTTAA								
W S A	P E L	G Q G	S S P	W L L	F T S								

FIG. 8

INTERLEUKIN-9 RECEPTOR VARIANTS

<u>PHENOTYPE</u>	<u>GENOTYPE</u>		
	ARG/ARG	ARG/HIS	HIS/HIS
ALLERGIC	1/18	8/18*	1/18*
NONALLERGIC	7/18	1/18	0/18
FISHER EXACT TEST P=0.002**			
* INCLUDES ASTHMATICS			
** ASSUMES ALLERGY IS AUTOSOMAL DOMINANT TRAIT			

FIG. 9

13 / 24




FIG. 10

14/24



FIG. II

15/24




FIG. 12

16/24




FIG. 13

17/24




FIG. 14A-1




FIG. 14C-1




FIG. 14E-1




FIG. 14G-1




FIG. 14I-1

18/24

FIG. 14B-1




FIG. 14D-1




FIG. 14F-1



FIG. 14H-1



FIG. 14J-1



19/24




FIG. 14A-2




FIG. 14C-2



FIG. 14E-2



FIG. 14G-2




FIG. 14I-2

20/24

FIG. 14B-2



FIG. 14D-2



FIG. 14F-2



FIG. 14H-2



FIG. 14J-2



21/24

FIG. 15A




FIG. 15B



FIG. 15C







FIG. 15D



22/24



23 / 24




FIG. 16

INTRON 5 POLYMORPHISM OF THE HUMAN IL-9 RECEPTOR

	90	100	110	120	130	↓ 140	150	
WT HUMAN IL-9 RECEPTOR SEQUENCE	AAGTGTGATG	AGTGTGAAAG	TGTTCCCTGTA	GACATGTTTG	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA>	
	AAGTGTGATG	AGTGTGAAAG	TGTTCCCTGTA	GACATGTTTG	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA	
MUTANT IL-9 RECEPTOR SEQUENCE	AAGTGTGATG	AGTGTGAAAG	TGTTCCCTGTA	GACATGTTTG	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA>	
	AAGTGTGATG	AGTGTGAAAG	TGTTCCCTGTA	GACATGTTTG	CCTGTGTGTG	CATATGTGTA	TTTGTGGGCA	

FIG. 17

[illegible]